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ABSTRACT 
 
 
 
SYNTHESIS, TESTING AND CRYSTALLOGRAPHIC STUDIES OF ALLOSTERIC 
MODIFIERS OF HEMOGLOBIN 
 
By Tanvi M. Deshpande, M.S. 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2013. 
 
Major Director: Dr. Martin Safo 
Associate Professor, Department of Medicinal Chemistry 
 
 
The major physiological function of hemoglobin (Hb) is to bind, transport and deliver oxygen to 
tissues; made efficient by endogenous effectors, such as protons and 2,3-diphosphoglycerate. 
Synthetic allosteric effectors of Hb (AEHs) are also known to modulate Hb oxygen affinity, 
showing potential for the treatment of sickle cell disease (SCD) and ischemic-related diseases. In 
this project, AEHs which increase Hb affinity for oxygen, including derivatives of the anti-
sickling compounds, 5HMF and benzaldehydes, as well as an AEH that decreases Hb affinity for 
xvii 
	  
oxygen, RSR-13, were synthesized for their effects on Hb oxygen binding property and their 
capability to release NO from substituted nitrate ester moieties. Compounds that were found to 
increase Hb affinity for oxygen were further tested for their anti-sickling activities. Structural 
studies were carried out to gain insight into the compound’s mode of action. Development of 
these agents could be a therapeutic strategy for SCD or ischemic-related diseases.  
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INTRODUCTION 
 
 
 
1. Hemoglobin – A target for drug design  
Human hemoglobin (Hb) is an allosteric protein that exists between the deoxygenated 
(tense or T) and oxygenated (relaxed or R) state.1 The major physiological function of Hb is to 
bind oxygen (O2) in the lungs and deliver it to the tissues.2 This function is regulated and/or 
made efficient by endogenous heterotropic effectors, such as 2,3-diphosphoglycerate (2,3-DPG), 
chloride (Cl-) and hydrogen ions (H+).3 2,3-DPG in the red blood cells (RBCs) preferentially 
bind to the deoxygenated Hb and stabilizes the T-state to decrease the Hb affinity for O2.4-6 This 
enables adequate O2 release to respiring tissue. Low pH, as a result of metabolism, leads to 
uptake of H+ by the protein which also stabilizes the T-state, with a concomitant release of O2 to 
the respiring tissues.7-10 Conversely, uptake of O2 by T-state Hb releases the H+ and the bound 
2,3-DPG from the T-state, with a concomitant stabilization of the R-state and an increase in the 
Hb oxygen affinity.  
A number of synthetic allosteric effectors of Hb (AEHs) are also known to bind to the 
protein and either increase or decrease its affinity for O2 by stabilizing or destabilizing one of the 
Hb states. The ability to allosterically regulate Hb ligand binding has been of significant interest 
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in medicine due to its wide range of applicability. For example, RSR-13 (Efaproxiral),11 and 
inositol hexaphosphate (IHPP)12 are AEHs that preferentially stabilize the T-state relative to the 
R-state to lower the affinity of Hb for O2 and enhance its delivery to tissues in a manner 
physiologically similar to 2,3-diphosphoglycerate (2,3-DPG). Physiologically, Hb releases 25% 
of O2 to tissues;13 therefore, these compounds have potential therapeutic applications in treating 
ischemia-related cardiovascular diseases, such as angina, myocardial ischemia, stroke, trauma, 
where more O2 is needed to heal tissue or organs.14-16  
A second class of AEHs, which includes vanillin and 5HMF, on the contrary, bind to Hb 
to increase its O2 affinity by preferentially stabilizing the R-state relative to the T-state. These 
compounds have been studied for the treatment of sickle cell disease (SCD).17,18 Sickle cell 
disease occurs as a result of a single point mutation of βGlu6 in normal hemoglobin (Hb A) to 
βVal6 in sickle hemoglobin (Hb S).19,20 This mutation creates a hydrophobic patch that allows 
stereospecific interactions between deoxygenated Hb S (deoxy-Hb S) molecules, causing 
polymerization inside red blood cells (RBCs).20,21 This leads to deformation of the RBCs into 
rigid sickle cells that occlude capillaries and small blood vessels. Compounding this problem is 
the fact that sickle Hb has low affinity for O2 due to high concentration content of 2,3-DPG, 
resulting in high concentration of deoxy-Hb that polymerize easily.22 Thus, AEHs that are able to 
increase O2 affinity of Hb behave as anti-sickling agents by preventing premature deoxygenation 
of sickle Hb, as well as reducing the concentration of deoxy-Hb S in RBCs. 
 
 
 
	  
	  
3	  
	  
2. Structure and function of Hb 
Hemoglobin is a tetrameric protein with a molecular weight of about 64,500, consisting 
of four subunits: two α-subunits (α1 and α2) containing 141 amino acids each, and two β subunits 
(β1 and β2) containing 146 amino acids each.23,24 Hemoglobin crystal structure in the liganded 
form was first solved by Perutz et al. in 1962 (Figure 1).25 Following that, the structure of the 
unliganded (deoxygenated) was determined.26 As shown in Figure 1, each tetramer has one heme 
moiety per subunit. The α-subunit consists of seven α helices – A through H with no D, while the 
β-subunit comprises of eight α helices – A through H.24,27 The four subunits are arranged into a 
distorted tetrahedral geometry showing a two-fold axis of symmetry and forming a large central 
water cavity.27 The central water cavity is narrower in the oxy-Hb than in the deoxy-Hb.28	  The α- 
and β-clefts define the two entry points into the central water cavity, with those of the T-state 
larger than the R-state. Each heme moiety has a heme prosthetic group which binds O2. The 
heme is coordinated with four nitrogens of the porphyrin ring in the equatorial plane and 
histidine (αHis87 at the α-heme and βHis92 at the β-heme) in the axial plane. When O2 binds to 
the heme, the iron-histidine residue comes into the plane of the porphyrin ring, whereas when no 
ligand is bound to the heme, the iron-histidine residue moves out of the plane of the porphyrin 
ring.3  
Hemoglobin exists in equilibrium between the R-state having high O2 affinity, and T-state 
possessing low O2 affinity state. 3,29 The T-and R-states of Hb provide a structural basis for Hb 
cooperativity that facilitates the efficient uptake and release of O2 in vivo.1 Based on the liganded 
or oxy-Hb and unliganded or deoxygenated structures of Hb, Max Perutz proposed a 
stereochemical mechanism to explain Hb cooperativity.8 He suggested that each subunit of the 
Hb tetramer goes through tertiary conformational change upon ligand binding, which is then 
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transmitted to the other subunits through direct communication between them. This leads to 
sequential increase in the ligand affinity at other heme sites, and thereby shifting the equilibrium 
towards the R-state.8 The converse is true for shifting the equilibrium to the T-state. This 
property of hemoglobin is depicted by the sigmoidal curve of O2 binding, which is also known as 
oxygen dissociation (ODC) or oxygen equilibrium curve (OEC) (Figure 2).30    
Several heterotropic effectors regulate the O2 affinity and cooperative behavior of Hb. 
These effectors include 2,3-diphosphoglycerate (2,3-DPG) (1), hydrogen ions (H+), carbon 
dioxide (CO2) and chloride ions (Cl−).3,31 This helps in maintaining Hb function of O2 transport 
and its delivery, effectively.32 2,3-DPG is an endogeneous allosteric effector of Hb which 
preferentially binds to the larger β-cleft of deoxy-Hb and stabilizes the T-state,28 allowing 
offload of O2 to the tissues. It does so by tying the two β-subunits together through several 
intersubunit hydrogen bond/ salt-bridge interactions to stabilize the T-state.5,28 To transition from 
T-state to R-state, the 2,3-DPG – mediated salt bridge/ hydrogen bonds must be broken and the 
2,3-DPG expelled out from the water cavity.   
 
 
 2,3-DPG (1) 
 
O-O
2-O3P
O
O PO32-
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Figure 1. Tetrameric structure of human hemoglobin with α (α1 - blue; α2 - grey) and β (β1 - 
magenta; β2 - yellow) chains and iron containing heme moieties.25 
 
 
 
 
α1	  
α2	  
β2	  
β1	  
	  
	  
6	  
	  
 
 
 
Figure 2. Sigmoidal curve of hemoglobin on O2 binding.30 
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The ligand releasing and binding properties of Hb are also dependent on the pH. The 
effect of [H+] on the equilibrium between the T- and R-states is known as Bohr’s effect. In 1904, 
Christian Bohr discovered that CO2/H+ have an effect on the O2 releasing or binding property of 
Hb. High concentration of CO2 in the tissues reduces the pH causing the O2 affinity of the Hb to 
decrease.33 It was shown later by Max Perutz that at acidic pH, protonated β1His146 participates 
in salt-bridge interactions with the carboxyl group of β1Asp94 and the amine of α2Lys40, which 
stabilizes the low affinity T-state structure to reduce the Hb affinity for O2.8 Vice versa, in the 
lungs, where pH is high due to the release of CO2, the O2 affinity of Hb is increased, allowing it 
to bind to O2.33 Mechanistically, at higher pH values, the above salt-bridges are broken, which 
increase the mobility of β1His146, shifting the allosteric equilibrium to the R-state.8 
Fetal hemoglobin (Hb F) is a form of Hb present in neonates until 6 months of age after 
which there is a switch from Hb F to adult hemoglobin (Hb A). Hb F contains 2 α-chains and 2 
γ-chains (instead of β-chains).34,35 The amino acid sequence in the γ-chain is about 72% similar 
to the β-chain. The only difference is that βHis143 is replaced by βSer143.36 This change 
eliminates two positive charges from the 2,3-DPG binding site and reduces affinity of Hb F for 
2,3-DPG, thereby increasing the O2 affinity of Hb F.37  
    
3. The oxygen equilibrium curve (OEC)  
The allosteric equilibrium between the two Hb states (Figure 2 and 3) shows a typical 
oxygen equilibrium curve (OEC) for Hb which is a plot of percent saturation of Hb (sO2) against 
the partial pressure of O2 (pO2).30 When the allosteric equilibrium shifts towards the R-state    
(left-shift of the curve), high affinity Hb is obtained that more readily binds to and holds O2. 
While a shift towards the T-state (right-shift of the curve) results in a low affinity Hb that more 
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easily offloads O2. The oxygen affinity of Hb is reported as P50, the partial pressure of oxygen in 
mmHg at which 50% of Hb is saturated with oxygen.37  
Figure 3 shows the shift in the OEC with varying pH, temperature and 2,3-DPG.38 The 
middle curve portrays the normal OEC for Hb. A decrease in pH, increase in temperature and/or 
increase in the red cell 2,3-DPG value, leads to a right-shift in the curve. This indicates that the 
deoxy (T) state of Hb is stabilized and there is a higher degree of O2 release at the same partial 
pressure of O2. If there is an increase in the pH, decrease in temperature and/ or red cell 2,3-DPG 
concentration, a left-shift in OEC is observed. This indicates that the oxy (R) state is stabilized 
and that the O2 affinity of Hb increases.  
As noted previously, there are also several allosteric effectors that can modulate the O2 
affinity of Hb. These compounds bind to the Hb to shift the allosteric equilibrium from T-state to 
R-state or vice versa. This allosteric property has been taken advantage of in medicine. For 
instance, agents that left-shift the OEC to produce high-O2-affinity Hb are potentially useful to 
treat SCD,39-41 while agents that right-shift the OEC to enhance and/or increase O2 delivery to the 
tissues are potentially useful for the treatment of hypoxic and ischemic-related diseases.42 
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Figure 3. Oxygen equilibrium (or dissociation) curve of hemoglobin. The normal P50 value is 
indicated by dashed lines. The left-shift and right-shift in the curves is associated with various 
conditions are indicated by dashed arrows.38   
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4. Abnormal human hemoglobins  
Abnormal human Hb can be broadly classified into two general categories of disorders 
namely, 1) Quantitative disorder, where there is a defect in the production of one of the subunits, 
either total or reduction, as in the case of thalassemia, and 2) where there is production of Hb 
variants, that is, structural defect in one of the globin chains, as in the case of SCD.  
There are two types of thalassemias: α-thalassemia and β-thalassemia. Decreased production of 
α-chains leads to α-thalassemia whereas decreased production of β-chains leads to β-
thalassemia.43 Figure 4 shows the geographical distribution of sickle cell disease, β-thalassemia 
and malaria.44 Since 50 years; scientists have noted the increased prevalence of SCD traits in 
malaria prone areas. It was soon discovered that Hb AS heterozygote (Hb A having SCD trait) 
has proven to protect from malarial infection and death caused by P. falciparum.45  
In 1949, Pauling et al.46 applied the method of electrophoresis to determine that SCD was 
caused by point mutation of Hb, where βGlu6 was converted to βVal6. Since then, capillary 
electrophoresis has been used to detect additional variants.47 These Hb mutants are mainly 
divided into four broad categories that exemplify important features of Hb biology:43                  
1) Unstable variants, involves loss of heme, followed by precipitation of globin in granular 
deposits; 2) High O2 affinity variants, involves Hb with high O2 affinity due to stabilization of R-
state relative to the T-state e.g. Hb Hiroshima (β146His to β146Asp);  3) Low O2 affinity 
variants, involves stabilization of T-state Hb (deoxy-Hb) relative to R-state, e.g. Hb Milwaukee; 
4) Methemoglobin “M-Type” variants, strongly favors the methemoglobin or the oxidized iron 
state. These usually involve change in the ligation of the heme iron e.g. Hb M Boston.  
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Figure 4. Geographical distribution of SCD, β-thalassemia and malaria.  
A. Distribution of Hb S allele; B. Distribution of malaria.44 
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5. Sickle cell disease 
Sickle cell disease (SCD) is an inherent genetic disorder characterized by sickled RBCs.48 
In 1910, James Herrick, a Chicago physician, reported the presence of sickle-shaped RBCs in a 
West Indian student.48,49 Normal RBCs are biconcave, donut shaped and are flexible enough to 
easily pass through the blood capillaries (Figure 5).18 On the other hand, sickled cells are sickle 
shaped and rigid (Figure 5), and hence cannot pass through blood capillaries freely, obstructing 
blood flow (vaso-occlusion).18 This leads to a condition called “painful crisis” which is 
characterized by hemolytic anemia, hypoxia, ulcers, stroke, and organ damage.44,48,49 Sickled 
blood cells are very fragile, leading to hemolysis causing the release of free Hb into the 
circulation. This free plasma Hb is a potent nitric oxide (NO) scavenger and results in the 
formation of reactive O2 species such as superoxide and peroxide radicals.44 Furthermore, the 
enzyme arginase released from the hemolyzed RBCs can deplete the plasma arginine levels. 
Arginine is important for NO production in the body by NO synthase.50 Nitric oxide is a potent 
smooth muscle relaxant and plays a critical role in vascular homeostasis by maintaining blood 
pressure. It is also a critical regulator of platelet activation and aggregation.51 Deficiency of NO 
from blood plasma, due to the scavenging property of cell-free Hb, is one of the symptoms of 
SCD and may lead to vaso-constriction followed by hypertension.52 
Sickle cell disease is widely prevalent in regions such as Africa, India, Caribbean, Central 
Mediterranean, South and Central America.44 More than 100,000 of the population of United 
States population suffer from this disease.53  
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Figure 5. A) Normal RBC discocytes, B) Sickle cell RBCs.18   
 
Almost 40 years after Dr. Herrick reported SCD, in 1949, Pauling and colleagues46 
identiﬁed electrophoretic anomalies in Hb S and came across the molecular basis for SCD. He 
coined the term “molecular disease” for SCD.44 The electrophoretic patterns, as shown in Figure 
6,54 determined that Hb S has less negatively charged residues as compared to Hb A, hence, Hb S 
migrates faster to the negatively charged cathode than Hb A.46 Patients who are heterozygotes, 
showing sickle cell trait and do not have symptoms of the disease, showed a mixture of Hb S and 
Hb A bands in the electrophoretic pattern.  
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Figure 6. Electrophoretic patterns showing normal, sickle-cell trait and sickle-cell disease Hb.54 
 
In 1957, Ingram sequenced the α- and β-chains of Hb and found a mutation at the 6th 
position of the β-chain.19 This mutation was caused by the substitution of glutamic acid (Glu), a 
polar amino acid, for valine (Val), a hydrophobic amino acid. This mutation in the amino acid is 
due to mutation in the β-globin gene (from A to T).20 In deoxy or T-state, the mutated Val 
residue of one Hb S makes contact with a hydrophobic pocket formed by Ala70, Phe85 and 
Leu88, which results in the formation of 14-stranded fibers.20,21 These fibers have reduced 
solubility and form aggregates which disrupt the cell membrane of RBCs.20 Polymerization is 
seen only in deoxy-Hb S since the hydrophobic pocket formed by Phe85 and Leu88 can make 
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contact with Val6 only in the deoxy-Hb S. Whereas in the oxy-Hb S, the pocket does not make 
hydrophobic contact with Val6,55 and therefore oxy-Hb S does not polymerize due to its 
increased solubility of 70 g/dl as compared to 17 g/dl for deoxy-Hb S.56 When Hb S gets re-
oxygenated at higher pO2 values, the sickling can disappear, and most RBCs eventually return to 
a normal shape.57 
Other studies on the gelation of deoxy-Hb S and various Hb variants have provided 
crucial information on other Hb contact points that are important in stabilizing the Hb S 
polymer.58 From the foregoing, it was realized that drugs capable of preventing stereospecific 
interactions between deoxy-Hb S molecules and/or increasing the O2 affinity of Hb S should 
increase its solubility and prevent cell sickling. 
 
6. Therapeutic strategies for SCD 
In the U.S., patients with SCD on an average survive until their 40s and suffer from poor 
quality of life and a burden of high medical cost. These statistics are far worse in patients from 
third world countries. Although a great deal of work has been done to find a cure for SCD, 
hydroxyurea is the only clinically available drug for the treatment of the same.40 Hydroxyurea 
enhances the production of Hb F; however it is poorly tolerated and can cause myelosuppression, 
requiring frequent monitoring for life-threatening side effects.59 Additionally, many people in the 
developing countries do not have access to this drug.59 One reason for the lack of success in 
finding a useful anti-sickling agent is due to the large amount of Hb present in the blood that 
requires treatment with high doses of a relatively nontoxic drug.18,60 The following categories 
describe the current therapeutic strategies directed to treat SCD: 
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a) Natural products: 
Several natural products have been reported to have anti-sickling effect.61  
The roots of Fagara zanthoxyloides are used in Nigeria and other western African countries. The 
active ingredients found in these roots are three divanilloylquinic acids which show anti-sickling 
effects.62 Apart from these, vanillic acid (2) and p-hydroxybenzoic acid (3) were also found in 
the root extracts, and are suggested to have anti-sickling activities. The unripe fruit or leaf of 
Carica papaya, containing phenylalanine (4) and tyrosine (5) is used in SCD.62 Niprisan, an 
herbal drug, was introduced in 2006 in Nigeria for the treatment of SCD. It constitutes extracts of 
four different plants namely Piper guineese, Pterocapus osun, Eugenia caryophyllum and 
Sorghum bicolor.63  
                                                                 
Vanillic acid (2)         p-Hydroxybenzoic acid (3)       phenylalanine (4)                Tyrosine (5)                      
b) Genetic:  
In 1948, Watson64 observed that the clinical manifestations of SCD are mild in infants 
with high levels of Hb F, as seen in patients from certain regions of Saudi Arabia65,66 and 
India.66,67 During the last few decades a lot of effort has been dedicated to the increase in Hb F 
levels of patients with SCD. Certain drugs including 5-azacytidine (6),68 gemcitabine (7)69 and 
decitabine70 were found to stimulate Hb F synthesis by inhibition of DNA methylation. Other 
agents such as erythropoietin,71 hydroxyurea (8),59,60 and butyrate (9)72 were found to increase 
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Hb F synthesis. In fact, hydroxyurea is the only FDA approved drug to treat patients with 
moderate to severe SCD.18,66   
                                  
5-Azacytidine (6)                    Gemcitabine (7)           Hydroxyurea (8)                   Butyrate (9) 
Other genetic methods for treatment of SCD include hematopoietic stem cell transplantation,73,74 
and blood and bone marrow transplantation.75,76 In 1982, St. Jude’s hospital was the first 
organization to find a cure for SCD by bone marrow transplantation method. Despite the 
beneficial effects of this method, it has several drawbacks which includes; the risk of bone 
marrow rejection, high cost of treatment, graft-versus-host disease and high mortality rates.77 
 
c) Membrane acting drugs:  
The polymerization of deoxy-Hb S leads to dehydration of RBCs, which in turn results in 
further polymerization of deoxy-Hb S. This vicious cycle is due to the fact that sickled cells have 
increased amounts of intracellular Ca2+. This increased Ca2+ concentration causes the activation 
of K+ efflux channel leading to dehydration of RBCs. Drugs that prevent loss of ions and water 
from the cell will help in preventing polymerization of Hb S. Cetiedel (10),78 a membrane acting 
drug, is found to inhibit Na+,K+ and Ca2+,Mg2+ ATPases, which results in the swelling of the red 
cell membrane and prevention of dehydration. Clotrimazole (11),79,80 an antifungal drug, and 
Bepridel (12),81,82 a Ca2+ channel antagonist, reduced cellular dehydration by blocking Ca2+-
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activated K+ channel (Gardos channel), thus maintaining the intracellular concentration of K+. 
Oral magnesium,80 which inhibits K+,Cl- co-transport channel, also shows the same effect. Other 
membrane active agents include Tellurite83 and L-Arginine (13).84 These compounds are shown 
to be toxic and hence not used regularly for SCD.85 
 
                                                                      
            Cetiedel (10)         Clotrimazole (11) 
                                          
             Bepridil (12)            L-Arginine (13) 
 
d) Stereospecific Acting Agents:  
Since the X-ray crystal structure of Hb was first determined,10,26,86 there have been 
several efforts to use it as a target to design stereospecific agents that would specifically interact 
with certain regions of Hb to destabilize polymer formation and/or increase the O2 affinity of Hb. 
These Hb modifying agents can be divided into three categories namely noncovalent, covalent 
and transient covalent acting agents/binders. 
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i) Noncovalent Hb binders: These agents bind noncovalently to the Hb S, mostly on the 
surface of the protein to destabilize polymers formation.87 A wide variety of agents belong to this 
class: Urea (14),88 alkyl urea,89 amino acids like phenylalanine,90 ethanol (15),91 tryptophan 
(16),90 and arylalanines,92 aromatic alcohols,93 oligopeptides,93 substituted aromatic carboxylic 
acids,94,95 and cromolyn sodium (17).96 One drawback of the noncovalent acting agents is that 
large doses are required for the treatment of SCD because of low-affinity to the surface of the 
protein.  
                                                       
 Urea (14)                                Ethanol (15)                           Tryptophan (16) 
 
                                     	   
                                           Cromolyn Sodium (17) 
 
ii) Covalent Hb binders: These agents form covalent interactions with Hb, stabilize the R-state 
Hb and/or destabilize the T-state Hb to shift the equilibrium to the R-state resulting in increase in 
the O2 affinity of Hb.87 These agents are quite promising since they can be administered at lower 
doses and less frequently. However, they lack specificity, in a way that, they could react 
covalently with other non-specific enzymes in the body, leading to toxicity. Examples are 
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cyanates (18),97 nitrogen mustards (19),98 ethacrynic acid (20),99 aspirin (21),100 acetyl 
phosphates (22),101 and cystamines (23).102 
	  	                                                                                
Cyanate (18)    Nitrogen mustard (19)              Ethacrynic acid (20) 
 
	                                                                     
    Aspirin (21)                       Methyl acetyl phosphate (22)                              Cystamine (23) 
 
iii) Transient Covalent binders of Hb: These agents include aldehyde-containing compounds 
that covalently interact with the amino terminus of Hb to form Schiff base adducts. These agents 
are known as transient covalent because they form transient bonds, which last only for a short 
period of time, as the Schiff base exists in equilibrium between the bound and the free state. By 
forming Schiff bases, they stabilize the R-state and/or destabilize the T-state of Hb, and increase 
the concentration of the more soluble oxy-Hb S to inhibit polymerization of Hb S. Examples of 
such compounds include vanillin (24),17,103 pyridoxal (25),103,104 aromatic aldehydes,3 12C79 
(27),105 5-hydroxymethyl-2-furfural (5HMF) (29),18 and pyridyl derivatives of benzaldehydes 
including INN-312(30) and INN-298 (31).106 Abraham et al.17 reported vanillin (which was 
studied in a phase I clinical trial) to bind at the N-terminal αVal1 of the α-cleft, as well as near 
αHis103, αCys104, and βGln131, and a site between βHis116 and βHis117, all contributing to its 
anti-sickling activity. 5HMF, is a naturally occurring anti-sickling compound found in a variety 
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of foods such as coffee, honey, fruit juices, dried fruits, alcohols etc. It is a promising new anti-
sickling agent that increases the O2 affinity of Hb in blood. It is also found to inhibit sickling of 
RBCs.18 It is currently in Phase I/IIa study for SCD treatment.106 Derivatives of vanillin have 
also been reported, and some of these compounds show as much as 70-fold more potency than 
vanillin.  These compounds also increase the O2 affinity of Hb by forming Schiff base adducts 
with the N-terminal αVal1.103 Other aldehyde containing compounds include substituted 
benzaldehydes, trans-cinnamaldehyde (26) and salicylaldehyde (28).107                 
 
  	  	   	  	  	  	  	  	  	  	   	   	   	   	  
    Vanillin (24)             Pyridoxal (25)         trans-Cinnamaldehyde (26)                 
  
	  	   	  	   	   	  	  	  	  	  	  	  	  	  	   	  	  	  	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
5HMF (27)	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  Salicylaldehyde (28)                  12C79 (29)                           
                            	  
    	  	  	  	  	  	  	  	  	   	   	   	    
INN-312 (30)         INN-298 (31) 
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e) Other Agents:  
Nitric oxide (NO)108,109 and organic NO releasing agents are used in SCD patients with 
NO deficiency. The free Hb present in the blood circulation after RBC lysis is a NO scavenger 
and takes up all the NO present in blood circulation. NO is a potent vasodilator, lack of which 
causes vaso-constriction and an increase in the blood pressure. Therefore NO therapy is 
beneficial in SCD patients to maintain blood homeostasis.  In addition to inhalation of NO, some 
of the clinically used NO donors include glyceryl trinitrate, sodium nitroprusside and isosorbide 
dinitrate, which release NO on in vivo metabolism.126 
 
7.  Compounds that bind to Hb and decrease its oxygen affinity 
During the search for drugs to treat sickle cell disease, researchers discovered several 
compounds including clofibrate94,110 and bezafibrate,111 which were found to lower the Hb O2 
affinity instead, by stabilizing the T-state of Hb and improve its O2 releasing capacity. The 
potential for use of these compounds to treat ischemic-related diseases were realized, resulting in 
the synthesis of more potent right-shifters including RSR-13 (32) and several of its analogs.112,113 
Crystallographic study of some of these compounds, including RSR-13 complexed with deoxy-
Hb, shows two molecules of the compound to bind along the central water cavity in a two-fold 
symmetry related fashion (Figure 7) to interact with both α- and β-subunits with a series of 
hydrogen-bonds and hydrophobic interactions that constrain the T-state Hb and prevent the 
allosteric shift to the R-state Hb.28  RSR-13 (Efaproxiral) was studied in several animal models 
for improving exercise capacity,114 hypoxia,28 ischemic injuries,14 and strokes. It was also studied 
for radiation therapy of hypoxic tumors by increasing the O2 supply to the tumors,115 and was 
studied in phase III clinical trial as an adjunct to radiation therapy in the treatment of brain 
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metastasis and the treatment of glioblastoma multiforme.113,117 It has also been studied for the 
development of blood substitutes.116 Researchers at Virginia Commonwealth University are 
currently studying RSR-13 to aid in the therapeutic release of gases, such as NO and CO.3  
 
 
                         RSR-13 (32) 
 
 
Figure 7. Binding of a pair of RSR-13 molecules (red spheres) to deoxy-Hb (PDB ID: 1G9V) 
with α (α1- blue; α2- grey) and β (β1- magenta; β2- yellow) chains.28 
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RATIONALE, OBJECTIVES AND SPECIFIC AIMS 
 
 
 
Rationale 
1. Aromatic aldehydes increase the oxygen affinity of Hb resulting in anti-sickling effect 
The mutation in Hb S creates hydrophobic interactions between deoxy-Hb molecules, 
causing polymerization inside RBCs, typically in capillaries where the partial pressure of O2 
(pO2) is low.55,117 This is exacerbated by the fact that Hb S has low O2 affinity due to the high 
concentration of 2,3-DPG, causing increased concentration of deoxy-Hb S. Unlike deoxy-Hb S, 
oxygenated Hb S (oxy-Hb S) does not polymerize.56 When Hb S gets re-oxygenated at higher 
pO2 values, the sickling disappears, and most RBCs eventually return to a normal shape. 
Therefore, compounds which are capable of increasing the O2 affinity of Hb S would prevent 
premature release of O2 and increase the oxy-Hb S concentration; thus preventing polymerization 
and RBC sickling. Several aromatic aldehydes, including 5-HMF (Figure 8a) and vanillin, as 
well as pyridyl derivatives of vanillin or benzaldehydes (INN compounds) have been studied for 
their anti-polymerization and anti-sickling properties.40,103 These compounds bind to Hb S by 
forming a Schiff base adducts between the aldehyde moiety and the N-terminal αVal1 nitrogen at 
the α-cleft of Hb (Figure 8b). The binding adds additional inter-subunit interaction across the 
subunit interfaces of oxy-Hb that lead to stabilization of the R-state. In contrast, binding at the α-
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cleft of deoxy-Hb leads to the destabilization of the T-state. As a result, the allosteric equilibrium 
is shifted to the R-state resulting in increased concentration of the more soluble oxygenated      
Hb S.18,106  
	  
5HMF (27)  
(a) 
 
(b) 
Figure 8. Binding of a pair of 5HMF molecules (red spheres) to R2-state Hb (PDB ID: 1QXE) 
with α (α1- blue; α2- grey) and β (β1- magenta; β2- yellow) chains.118  
 
Vanillin was studied before 5HMF,17 but because of its low potency and lack of activity 
when administered orally, the phase I clinical study was terminated. To improve on the 
pharmacological properties (allosteric and anti-sickling potency, and oral bioavailability) of 
vanillin, several pyridyl derivatives of vanillin, e.g. INN-312 (30), INN-298 (31), INN-270 (33) 
and INN-296 (34) were synthesized and tested.103 Some of these compounds, including INN 270, 
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INN-298 and INN-312 showed as much as 70-fold and 2.5-fold more potency than vanillin and 
5HMF, respectively, in preventing RBC sickling.106 These compounds also showed longer 
duration of action than vanillin and 5HMF.119 Some of the INN compounds such as INN-312 
(Figure 9a & 9b) showed dual anti-sickling effect. In addition to increasing the O2 affinity of Hb, 
these compounds directly destabilize polymer contacts between deoxy-Hb S molecules to inhibit 
RBC sickling as a result of the substituted pyridine-methoxy substituent (ortho to the aldehyde 
moiety) being directed towards the surface of the Hb.106 Nonetheless, INN compounds that also 
bind and direct their meta-positioned pyridine-methoxy substituent (relative to the aldehyde 
moiety) down the central water cavity also showed significant left-shifting and anti-sickling 
potencies as a result of additional interactions between the protein and the pyridine-methoxy 
substituent.106  
 
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   	  
               INN-312 (30)                         INN-298 (31) 
 
	        
     INN-270 (33)                     INN-296 (34)     
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INN-312 (30) 
(a) 
 
(b) 
Figure 9. Binding of a pair INN-312 molecules (red spheres) to R2-state Hb (PDB ID: 3R51) 
with α (α1- blue; α2- grey) and β (β1- magenta; β2- yellow) chains.106 
 
Based on the significant improvement in the pharmacologic properties of the INN 
compounds, as well as the dual anti-sickling effect of some of these agents, we decided to 
derivatize the INN compounds for further improvement in their pharmacologic properties.  
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Structure-based drug design:	  	  
	  
-OCH3 4, 5 
-X-R’ 2, 3 
X O, NH 
Y C=O 
N 2’, 4’ 
R H, CH2OH 
Figure 10. Basic scaffold of the INN compounds with structural modifications.103 
Figure 10 shows the core structure of the INN compounds, and several modifications which 
includes the methoxy group positions, the linker between the pyridine ring and the benzaldehyde 
ring, and the pyridine nitrogen positions. These modifications have previously been made 
culminating in several of these compounds having potent anti-sickling effects, including        
INN-312, INN-298, INN-296, etc.103 For this project, we decided to further modify the INN core 
structure as summarized in Figure 10 for further improvement in the biological activities of these 
compounds. The modifications include: 
(1) Replacing the ether linkage between the pyridine and the benzaldehyde ring with an ester 
or amide linkage in addition to varying the position of the methoxy and pyridine-methoxy 
substituents on the benzaldehyde ring. Two compounds were synthesized including TD-2 (35) 
and TD-3 (36) depending on the availability of starting materials, ease of synthesis, and time 
constraints. We hypothesized that these compounds would result in greater left-shifting activities 
by binding with higher affinity to the R-state Hb through additional interactions involving the 
ester or amide moieties.  
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(2) Introducing a hydroxymethyl group on the pyridine ring in addition to varying the 
methoxy and pyridine-methoxy substituent positions was hypothesized to increase the polymer 
destabilization property and/or binding affinity of the INN compounds. Based on the observation 
that INN compounds with the pyridine-methoxy group ortho (INN-312) or meta (INN-298) to 
the aldehyde functional group resulted in significant increase in the left-shifting potencies (with 
the former class of compounds exhibiting polymer destabilization effects), we decided to extend 
the pyridine-methoxy moieties by incorporating a hydroxymethyl group onto the pyridine ring 
for increased biological activities.106 Three compounds, including TD-7 (37), TD-9 (38) and TD-
8 (39) were synthesized out of all the possible combinations of the substituents depending on the 
availability of starting materials, ease of synthesis, and time constraints.   
The derivatives are positional isomers (TD-7, TD-8 and TD-9) with difference in the positions of 
the methoxy and hydroxymethyl-pyridine-methoxy substituent.  
 
	  	   	   	   	   	  	  	  	  	  	   	   	  
     TD-2 (35)                                  TD-3 (36) 
 
             
      TD-7 (37)              TD-9 (38)            TD-8 (39) 
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2. Aromatic aldehyde with NO releasing ability will be beneficial for sickle cell disease  
One of the indications of SCD is hemolytic anemia.44 In sickle cell patients, the increased 
rigidity of sickled RBCs leads to their rupture or lysis, releasing Hb which is a potent scavenger 
of NO.120 Along with the property of vascular dilatation, NO is also known to possess anti-
inflammatory property and it has applicability in neurotransmission.121  
Due to this scavenging property of Hb, SCD patients have been shown to suffer from NO 
deficiency, which consequently leads to hypertension and inflammation. This has prompted a 
great interest in developing means to deliver NO exogenously or enhance endogenous production 
for therapeutic purposes.122 For instance, inhaled NO has been shown to have beneficial effects 
in SCD patients by reducing the severity and duration of Hb S-induced vaso-occlusive or pain 
crisis and provide protection during ischemic related diseases, such as pulmonary arterial 
hypertension, cardiovascular diseases and acute lung distress syndrome.123-125 In addition to NO 
inhalation, several NO-donating compounds, e.g. aspirin, S-nitrosocysteine, pyrazoles, 
polynitroxy-albumin, nitroxic-albumin, detaNONOate, thalidomides, and indoles have been 
shown to have vasodilatory effect and/or reduce inflammation and/or hypoxia induce lung 
damage in SCD patients or mouse models.126,127 
From the foregoing, an anti-sickling agent that not only prevents polymer formation but 
also makes NO available to mitigate several SCD pathological conditions, would provide a novel 
and rational approach for efficiently preventing/counteracting SCD episodes and help limit 
disease progression. 
We used our lead anti-sickling compound, 5HMF, as well as some left-shifting 
compounds synthesized during this project, including TD-7 (37), TD-9 (38) and TD-8 (39) (see 
results below) to introduce nitrate ester moieties, resulting in the synthesis of TD-1 (40), TD-7-1 
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(41), TD-9-1 (42) and TD-8-1 (43), respectively. It was hypothesized that in vivo the nitrate ester 
would hydrolyze to release NO into the vasculature for its vasodilatory and anti-inflammatory 
activities,109 while the released parent aromatic aldehyde compound, would then participate in 
Schiff base interactions with the amino group of the N terminal αVal1 to increase the O2 affinity 
of Hb S.  
	   	   	   	  
                        TD-1 (40)                      TD-7-1 (41)	  
	  
	   	   	    
                         TD-9-1 (42)             TD-8-1 (43) 
 
3. A right-shifting allosteric effector with NO releasing ability 
RSR-13 is a potent AEH that increases the O2 releasing capacity of Hb by decreasing Hb 
affinity for O2. The compound binds and stabilizes the deoxy-Hb or T-state Hb relative to the 
oxy-Hb and shifts the OEC to the right or T-state to increase the release of O2 to tissues, 
potentially useful for treating diseased states that are characterized by O2 deficiency.113,128,129 A 
potential problem with the use of right-shifting agent is that excessive tissue oxygenation could 
induce secondary vasoconstriction and compromise blood flow.130 It seems that a right-shifting 
	  
	  
32	  
	  
agent with the ability to release NO could potentially mitigate this problem by its vasodilation 
property. Based on the foregoing, we derivatized RSR-13 with a NO releasing moiety to obtain 
the compound DD-1 (44). 
 
 
DD-1 (44) 
 
Objectives: 
There are two main objectives for this project: 
(1) Design allosteric effectors of Hb (AEH) that increase the oxygen affinity of Hb (left-shifting 
of the OEC) with and without the capability of releasing nitric oxide (NO) for the treatment of 
sickle cell disease  
(2) Design allosteric effectors of Hb (AEH) that not only decrease the oxygen affinity of Hb 
(right-shifting of the OEC) but also capable of releasing nitric oxide (NO) for the treatment of 
ischemic-related diseases. 
 
 
 
 
	  
	  
33	  
	  
Specific aims:  
There are two specific aims: 
Specific Aim 1:  
A. Synthesis of allosteric effectors that increase the oxygen affinity of Hb with or without NO 
releasing moieties 
i. Derivatization of INN compounds by substituting the ether linkage with amide or ester 
linkage to obtain TD-2 and TD-3 
ii. Derivatization of INN compounds by incorporating hydroxymethyl moiety on the 
pyridine ring to obtain TD-7, TD-8 and TD-9 
iii. Synthesis of nitrate ester derivatives including TD-1, TD-7-1, TD-8-1 and TD-9-1 that 
can act as anti-sickling agents, as well as donate NO to the vasculature. 
B. Determine in vitro functional and anti-sickling activities of the synthesized compounds 
i. Concentration- and time-dependent oxygen equilibrium curve study with whole blood 
and cell-free Hb 
ii. NO-releasing ability of the nitrate ester derivatives  
iii. RBC morphological (anti-sickling) study 
C. Determine the atomic interactions between Hb and selected compounds  
D. Stability studies of left-shifting nitrate ester compounds 
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Specific Aim 2: 
A. Synthesis of nitrate ester derivative of RSR-13 (DD-1) that can act as anti-ischemic agents, 
as well as donate NO to the vasculature 
B. Determine in-vitro functional and allosteric activity of DD-1 
i. Time-dependent oxygen equilibrium curve study with whole blood  
ii. NO-releasing ability of the nitrate ester derivative 
C. Determine the atomic interactions between Hb and DD-1 
D. Stability studies of DD-1 
 
 
	  
	  
35	  
	  
 
 
RESULTS  
 
 
 
Objective 1: Allosteric effectors of Hb (AEH) that increase the oxygen affinity of Hb (left-
shifting of the OEC) with or without the capability of releasing nitric oxide (NO) for the 
treatment of sickle cell disease 
A. Synthesis of AEHs with or without NO-releasing moieties  
 
i. Synthesis of pyridyl derivatives of benzaldehydes (TD-2, TD-3, TD-7, TD-8, TD-9): 
Vanillin, a benzaldehyde, exhibits anti-sickling action by increasing the O2 affinity of Hb, as 
well as inhibiting direct polymerization of Hb S.17,103 Derivatization of vanillin by incorporating 
substituted methoxy-pyridines on the aromatic aldehyde have resulted in several more potent 
anti-sickling pyridyl benzaldehyde compounds (referred to as INN compounds; compounds 30, 
31, 33 and 34 or INN-312, INN-298, INN-270 and INN-296 respectively). Some of these 
compounds, such as INN-312, INN-298 and INN-270, are 40-90 fold more potent than 
vanillin.103 In this project, we decided to modify the INN compounds for further improvement in 
their pharmacologic activities. The modifications included (1) replacing the ether linkage that 
connects the aromatic aldehyde and pyridine with an ester linkage (bridge), (2) replacing the 
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ether linkage with an amide linkage (bridge), (3) incorporating a hydroxymethyl moiety on the 
pyridine ring. Five compounds were synthesized which included TD-2 (35), TD-3 (36), TD-7 
(37), TD-9 (38) and TD-8 (39). 
Compound TD-2 (35) with an ester linkage between the benzaldehyde and pyridine moieties was 
synthesized as outlined in Scheme I. Esterification reaction was carried out by linking 
isonicotinylchloride hydrochloride (47) to a solution of 2-hydroxy-5-methoxybenzaldehyde (46) 
in pyridine at 0 °C to give 35 in 13% yield. 
SCHEME I: Synthesis of compound 35a 
 
aReagent: (a) pyridine, reflux, 2 h.  
 
Compound TD-3 (36) with an amide linkage between the benzaldehyde and pyridine moieties 
was synthesized as outlined in Scheme II. 5-Hydroxy-2-nitrobenzaldehyde (48) was alkylated 
using methyl iodide under basic conditions to give 49, followed by reduction of the nitro group 
to an amine in the presence of Fe/HCl to give 50. Amidation reaction was carried out by reacting 
a solution of 50 in DMF with isonicotinylchloride hydrochloride (47) to give 36 in 10% yield. 
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SCHEME II: Synthesis of compound 36a 
 
aReagent: (a) CH3I, K2CO3, anhydrous DMF, room temperature, 12 h; (b) Fe, HCl, EtOH, H2O, 
reflux, 2 h; (c) isonicotinylchloride HCl, pyridine, CH2Cl2, room temperature, overnight. 
 
Compound TD-7 (37) with a hydroxymethyl group on the pyridine ring was synthesized as 
shown in Scheme III. 2-Hydroxy-5-methoxybenzaldehyde (46) and 6-(bromomethyl)-2-
pyridinemethanol (51) were reacted together under basic condition at room temperature for 12 h 
to give 37 in 78% yield. 
SCHEME III: Synthesis of compound 37a 
 
aReagent: (a) K2CO3, anhydrous DMF, room temperature, 12 h. 
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Compound TD-9 (38) with a hydroxymethyl group on the pyridine ring was synthesized as 
shown in Scheme IV. 2-Hydroxy-4-methoxybenzaldehyde (52) and 6-(bromomethyl)-2-
pyridinemethanol (51) were reacted together under basic condition at room temperature for 12 h 
to give 38 in 71% yield.  
SCHEME IV: Synthesis of compound 38a 
 
aReagent: (a) K2CO3, anhydrous DMF, room temperature, 12 h. 
 
Compound TD-8 (39) with a hydroxymethyl group on the pyridine ring was synthesized as 
shown in Scheme V. 3-Hydroxy-4-methoxybenzaldehyde (53) and 6-(bromomethyl)-2-
pyridinemethanol (51) were reacted together under basic condition at room temperature for 12 h 
to give 39 in 82% yield. 
SCHEME V: Synthesis of compound 39a 
 
aReagent: (a) K2CO3, anhydrous DMF, room temperature, 12 h. 
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ii. Synthesis of nitrate ester derivatives of 5HMF and pyridyl derivatives of benzaldehydes 
(Dual–acting NO–releasing hybrid anti-sickling agents) (TD-1, TD-7-1, TD-8-1 and TD-9-1):  
 
It has been shown that SCD patients have NO deficiency as a result of scavenging of NO by free 
Hb S which consequently leads to hypertension and inflammation; common pathological 
conditions in SCD.121 We synthesized compounds that combine left-shifting and NO donor 
abilities not only to increase the solubility and prevent polymerization of Hb S but also have the 
potential to deliver NO to the vasculature. The compounds include the nitrate ester derivative of 
5HMF (TD-1 or 40), as well as nitrate ester derivatives of pyridyl derivatives of benzaldehydes 
(TD-7-1 or 41, TD-8-1 or 43, TD-9-1 or 42).  
 
Compound TD-1 (40), a nitrate ester of 5HMF, was synthesized as shown in Scheme VI. 5-
Hydroxymethyl-2-furfural (27) was nitrated directly using lithium nitrate and trifluoroacetic 
anhydride under basic conditions at 0 °C to give 40 in 85% yield.  
SCHEME VI: Synthesis of compound 40a 
 
 
aReagent: (a) LiNO3, TFAA, Na2CO3, anhydrous CH3CN, 0 °C, 7 h.                      
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Compound TD-7-1 (41), a nitrate ester of pyridyl derivative of benzaldehyde, was synthesized as 
shown in Scheme VII. Solution of 2-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-5-
methoxybenzaldehyde (37) was reacted with  triphenylphosphine and tetrabromomethane to 
yield 54 which was converted to the nitrate ester using silver nitrate at 80 °C to give 41 in 69% 
yield. 
SCHEME VII: Synthesis of compound 41a 
 
aReagent: (a) PPh3, CBr4, anhydrous CH2Cl2, room temperature, 2 h; (b) AgNO3, anhydrous 
CH3CN, 80 °C, 2 h. 
 
Compound TD-9-1 (42), a nitrate ester of pyridyl derivative of benzaldehyde, was synthesized as 
shown in Scheme VIII. Solution of 2-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-4-
methoxybenzaldehyde (38) was reacted with triphenylphosphine and tetrabromomethane to yield 
55 which was converted to nitrate ester using silver nitrate at 80 °C to give 42 in 55% yield. 
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SCHEME VIII: Synthesis of compound 42a 
	  
aReagent: (a) PPh3, CBr4, anhydrous CH2Cl2, room temperature, 2 h; (b) AgNO3, anhydrous 
CH3CN, 80 °C, 2 h. 
 
Compound TD-8-1 (43), a nitrate ester of pyridyl derivative of benzaldehyde, was synthesized as 
shown in Scheme IX. Solution of 3-((6-(hydroxymethyl)pyridine-2-yl)methoxy)-4-
methoxybenzaldehyde (39) was reacted with triphenylphosphine and tetrabromomethane to yield 
56 which was nitrated using silver nitrate at 80 °C to give 43 in 81% yield. 
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SCHEME IX: Synthesis of compound 43a 
	  
aReagent: (a) PPh3, CBr4, anhydrous CH2Cl2, room temperature, 2 h; (b) AgNO3, anhydrous 
CH3CN, 80 °C, 2 h. 
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B. In-vitro functional and anti-sickling studies 
The synthesized compounds were studied for their effect on Hb affinity for O2 (OEC 
study). The nitrate ester compounds were also studied for their ability to release NO (Griess 
study). Finally, selected compounds that increase Hb affinity for oxygen were studied for their 
ability to prevent RBC sickling (RBC morphological study).  
The OEC study was performed for all the synthesized compounds with 5HMF as a 
positive control using 3-point tonometry.103 Studies were carried out using normal whole blood 
(AA) or sickle whole blood (SS) or cell-free Hb A. The measured pO2 (partial pressure of 
oxygen) and sO2 (percent saturation of Hb) values were used to estimate P50 and N values of the 
effectors. P50 is the partial pressure of O2 required to achieve 50% Hb saturation. Hill coefficient 
(N) is the cooperative binding of O2 or ligand to Hb, and is normally 2.8 for normal human 
blood. ΔP50 values were calculated by subtracting the P50 value obtained for Hb post incubation 
with the effector from that of the control. A decrease in the P50 value (negative ΔP50) results in 
the left-shift of the OEC curve which indicates increased affinity of Hb for O2 as a result of 
stabilization of the oxy-Hb or R-state Hb. Such compounds are potential anti-sickling agents 
since high-O2-affinity sickle Hb does not polymerize. On the other hand, an increase in the P50 
value (positive ΔP50) results in the right-shift of the OEC curve, which indicates stabilization of 
deoxy-Hb or T-state Hb. Such compounds allow release of more O2 to tissues, potentially useful 
for treating ischemic-related diseases.15 
The compounds that were derivatized with nitrate esters were further studied to determine 
their ability to release NO from the nitrate ester moieties. NO is detected in the form of nitrite 
ions (NO2-) which develops an intense purple color in the presence of Griess reagent. The color 
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intensity measured in the form of absorbance is directly proportional to the nitrite concentration 
in the sample.10,11    
Finally, some of the compounds that left-shift the OEC or increases Hb affinity for O2 
were studied for their anti-sickling activity. This involves in vitro RBC morphological (anti-
sickling) studies, which were conducted by our collaborators, Drs. Toshio Asakura and Osheiza 
Abdulmalik, from the Children’s Hospital of Philadelphia, (CHOP). 
 
i. Oxygen equilibrium curve (OEC) studies 
a. OEC study of compounds TD-2, TD-3, TD-7, TD-7-1, TD-8, TD-8-1, TD-9 and TD-9-1 with 
normal whole blood: 
Studies were performed on compounds TD-2, TD-3, TD-7, TD-7-1, TD-8, TD-8-1, TD-9 
and TD-9-1 using 100 mM stock solution in DMSO and normal whole blood (AA). As noted 
above, TD-2 and TD-3 are the compounds with an ester and amide linkage; TD-7, TD-8 and   
TD-9 are the compounds with hydroxymethyl substituent on the pyridine ring, while TD-7-1, 
TD-8-1 and TD-9-1 are their respective nitrate ester derivatives. The compound solution was 
added to 2 mL of whole blood (Hematocrit value of ~ 34%) to make final drug concentration of 
2 mM. Hematocrit or packed cell volume is the % volume of RBCs present in the blood.131 The 
solutions were incubated for 1 ½ hours at 37 °C, equilibrated in a tonometer with O2 tensions of 
6%, 20% and 40% for 5-7 min each, and pO2 and sO2 values were measured thereafter using 
ABL 700 series table top automated blood gas analyzer (Radiometer America, Inc., Westlake, 
OH). 5HMF was known to exhibit optimal left-shifting activity between 1 to 2 h with peak effect 
at 1.5 h when incubated with whole blood necessitating the use of 1.5 h for the incubation time 
for our studies.18,119 The results are shown in Table 1 and Figure 11. 
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 Table 1. Effects of left-shifting compounds on Hb affinity for O2 with normal whole blood. 
Compound 
Concentration 
(mM) 
P50 
(mmHg) 
Na 
ΔP50b 
(mmHg) 
5HMF 2 20.2 ± 2.0c† 1.8 ± 0.1c† -11.1 
TD-2  2 30.5d† 2.3d† -0.8 
TD-3  2 44.4d† 1.5d† +13.1 
TD-7 
0.1 30.1d* 2.5d* -0.5 
0.5 25.9d* 2.1d* -4.7 
1 23.2d* 1.7d* -7.4 
2 14.3 ± 4.3c† 1.3 ± 0.3c† -17.0 
TD-8 2 25.9 ± 2.5c† 1.9 ± 0.1c† -5.4 
TD-9 2 21.1 ± 1.2c† 1.6 ± 0.3c† -10.2 
TD-1 2 27.4 ± 2.3c† 1.9 ± 0.1c† -3.9 
TD-7-1 2 23.4 ± 1.6c† 1.7 ± 0.1c† -7.9 
TD-8-1 2 30.8d† 2.1d† -0.5 
TD-9-1 2 28.6d† 1.9d† -2.7 
All samples were pre-incubated with whole blood (Hct ~ 34%) with the specified compounds at 
given concentrations for 1 ½ h. †P50 values of test compounds were calculated using control	  P50 
value of 31.3 ± 1.8 mmHg;	   †Control N value is 2.6 ± 0.1; *P50 values of test compounds were 
calculated using control	  P50 value of 30.6 mmHg; *Control N value is 2.6;	  aHill coefficient; bΔP50 
is (P50 (control)–P50 (sample)) expressed in mmHg; cmeasurements were conducted in n ≥ 3; 
dmeasurements were conducted in n < 3. The control experiment without test compound (P50 
(control)) contains the same concentration of DMSO used to solubilize the test solution (P50 
(sample)).  
 
Although all the compounds were designed to left-shift the OEC and increase the O2 
affinity of Hb, quite unexpectedly, TD-3 (amide linker) showed the opposite effect by right-
shifting the OEC by ΔP50 of 13 mmHg and decreasing Hb affinity for oxygen (Table 1). The rest 
of the compounds left-shifted the OEC by varying amounts. The least potent were TD-2 (ester 
linker) and TD-8-1 (the nitrate ester of TD-8) which barely shifted the curve (< 1 mmHg). These 
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values are well within the experimental error and may not be significant. The inactivity of TD-2 
can be probably attributed to the aldehyde dehydrogenase (ALDH) metabolism or metabolism by 
esterases inside the RBCs that cleave or metabolize the ester linkage. The most potent left-shifter 
was TD-7 (hydroxymethyl analog of INN compounds) with a ΔP50 shift of -17.0 mmHg; more 
potent than 5HMF (ΔP50 of -11.1 mmHg) and comparable in potency with INN-312.119 Studies 
also showed a concentration-dependent left-shift of the OEC for TD-7 (Table 1).  
 Although, the other hydroxymethyl derivatives, including TD-8 and TD-9, left-shifted 
the OEC (ΔP50 of -5.4 and -10.2 mmHg, respectively), the shifts were found to be significantly 
less than 5HMF, as well as their parent INN compounds (without the hydroxymethyl moiety) 
which exhibited ΔP50 of -14 mmHg and -16 mmHg, respectively.119 As discussed below, it is 
possible that TD-8 and TD-9 could either be binding to plasma protein or perhaps having 
difficulties in RBC permeation.  
The nitrate ester derivatives showed 2.5-10 fold less potency when compared with the 
parent compounds. This observation is probably due to the fact that the nitrate esters did not 
hydrolyze completely to release the parent molecule to effect maximum left-shifting activity 
and/or may be due to RBC membrane permeability issues or plasma protein binding. As 
expected the compounds have major effect on Hb cooperativity (N values), as the shape of the 
OEC changed from sigmoidal to hyperbolic with addition of the compound.  Similar effect on 
cooperativity has been reported for 5HMF,18 INN-312,103 and RSR-13.116 This is a result of the 
effectors stabilizing either the T- or R-state Hb and thus restraining a cross-talk between the Hb 
subunits which is important for the T-R transition.  
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Figure 11. OEC of left-shifting compounds at 2 mM concentration incubated for 1 ½ h. 
 
b. OEC study of compounds TD-1, TD-7, TD-7-1, TD-8 and TD-9 with normal cell-free Hb: 
As a result of the weak left-shifting activities of TD-8 and TD-9, and the nitrate ester derivatives, 
we further evaluated the activity of some of the compounds, including TD-1, TD-7, TD-7-1, TD-
8, and TD-9 using cell-free Hb (devoid of any proteins, enzymes, plasma and cell membranes). 
This experiment was performed to determine whether the plasma protein or RBC membrane 
could have any effect on compound biological activity. Previous studies have shown limited 
effect of plasma protein and RBC membrane on 5HMF, INN-312 and INN-298 activities.18,106 
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Similar tonometry procedure used on whole blood was used with the cell-free Hb using 2 mM 
compound and 12 g/dL of Hb. The results are shown in Table 2. 
Table 2. Effects of left-shifting compounds on Hb affinity for O2 with cell-free Hb. 
Compound 
P50 
(mmHg) 
Na 
ΔP50b 
(mmHg) 
Control 12.5  2.6 - 
5HMF 8.3 2.0 -4.2 
TD-7 7.6 1.8 -4.9 
TD-8 7.6 1.9 -4.9 
TD-9 6.8 1.7 -5.7 
TD-1 8.4 2.0 -4.1 
TD-7-1 7.7 2.1 -3.9 
All samples were pre-incubated with purified Hb A (Hb ~ 12 g/dL) with the specified compounds 
at 2 mM concentrations for 1½ h. aHill coefficient; bΔP50 is (P50 (control)–P50 (sample)) 
expressed in mmHg; measurements were conducted in n = 1. The control experiment without test 
compound (P50 (control)) contains the same concentration of DMSO used to solubilize the test 
solution (P50 (sample)).  
 
Unlike the results obtained from the whole blood study (Table 1), the results depicted in 
Table 2 show that all compounds exhibit significant left-shift in the OEC with cell-free Hb. TD-8 
which barely shifted the OEC with whole blood now showed a shift comparable to TD-7 with 
cell-free Hb. TD-9 appeared to be an even more potent left-shifter in cell-free Hb than TD-7, 
which was opposite to what was observed with whole blood. Although, the nitrate esters still 
show less left-shift compared to the parent compounds, there is still significant improvement in 
their left-shifting potency with cell-free Hb. These observations suggest that the reduced left-
shifting activities of some of the compounds could be partly due to RBC membrane permeability 
and/or plasma protein binding issues.  
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c. Time-dependent OEC studies with TD-7:  
Studies with INN-312 and INN-298 showed the compounds to exhibit longer left-shifting 
effect compared to 5HMF119 prompting us to conduct similar experiments with TD-7 along with 
the positive control, 5HMF, all at 0.5 mM concentration for a time period of 1 h – 12 h. The 
results are shown in Table 3 and Figure 12. 
Table 3. Effect of incubation time on Hb affinity for O2 with whole blood for left-shifting 
compounds. 
Compound Incubation Time (Hours) 
P50 
(mmHg) N
a ΔP50b 
(mmHg) 
Control 
1 32.7 ± 0.2c 2.5 ± 0.1 c - 
2 33.0 ± 0.4c 2.5 ± 0.1 c - 
4 33.1 ± 0.6 c 2.5 ± 0.1 c - 
6 34.2 ± 0.3 c 2.5 ± 0.1 c - 
10 35.1 ± 0.3 c 2.5 ± 0.1 c - 
12 36.1 ± 0.4 c 2.4 ± 0.1 c - 
5HMF 
1 29.8 ± 0.2 c 2.2 ± 0.1 c -2.9 
2 29.2 ± 0.3 c 2.2 ± 0.1 c -3.8 
4 29.2 ± 0.1 c 2.1 ± 0.1 c -3.9 
6 30.0 ± 0.1 c 2.1 ± 0.1 c -4.2 
10 31.8 ± 0.1 c 2.1 ± 0.1 c -3.3 
12 32.8 ± 0.1 c 2.0 ± 0.1 c -3.3 
TD-7 
1 28.2 ± 0.9 c 2.2 ± 0.2 c -4.5 
2 28.2 ± 0.8 c 2.1 ± 0.1 c -4.8 
4 28.8 ± 0.6 c 2.1 ± 0.1 c -4.3 
6 29.1 ± 0.6 c 2.0 ± 0.2 c -5.1 
10 30.6 ± 1.0 c 2.0 ± 0.1 c -4.5 
12 31.1 ± 0.7 c 2.0 ± 0.2 c -5.0 
All samples were pre-incubated with whole blood (Hct ~ 34%) with the specified compounds at 
0.5 mM concentrations for the specified time. aHill coefficient; bΔP50 is (P50 (control)–P50 
(sample)) expressed in mmHg; cmeasurements were conducted in n ≥ 3. The control experiment 
without test compound (P50 (control)) contains the same concentration of DMSO used to 
solubilize the test solution (P50 (sample)).  
 
The P50 values of control were found to increase consistently, with incubation. While the 
P50 values for 5HMF seem to return to baseline after 6 h, there was no recovery for TD-7 even 
after 12 h suggesting TD-7 will have a longer sustained effect similar to INN-312 (Figure 11). 	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Figure 12. Time dependent studies of TD-7 showing change in P50 value with incubation time. 
 
ii. NO release study for compounds TD-1, TD-7-1, TD-8-1 and TD-9-1  
Following the OEC studies, Griess assay was performed on the left-shifting nitrate ester 
compounds (TD-1, TD-7-1, TD-8-1, and TD-9-1) to measure the release of NO. Griess assay is a 
colorimetric assay, used for detection of NO in the form of nitrite ions (NO!!). NO released in 
solution is highly unstable, with a half-life of 1 to 30 s. It gets rapidly oxidized to NO!! which is 
detected by the Griess reagent. In this method, NO!! first reacts with the sulfanilamide present in 
the reagent to form a transient diazonium salt. This diazonium salt further reacts with                 
N-naphthyl-ethylenediamine (NED) to form a stable azo compound which possesses an intense 
purple color. The absorbance of the azo compound was measured at 540 nm and was found to be 
directly proportional to the NO!! concentration in the sample.132,133 Sodium nitrite (NaNO2) was 
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used as a standard for the Griess assay. Standard NaNO2 curve was obtained according to an 
assay procedure.134 NaNO2 samples in deionized water were prepared of concentrations within 
the linear range of the assay (1 – 100 µM). The samples were incubated for 30 min at 37 °C, after 
which Griess reagent was added and absorbance was measured at 540 nm. The measured 
absorbances were used to obtain a standard curve (Figure 13).134 For the measurement of NO!!  
release for all the test compounds (TD-1, TD-7-1, TD-8-1 and TD-9-1), the absorbances were 
extrapolated from the standard NaNO2 curve. 
 
 
Figure 13. Standard sodium nitrite curve of absorbance vs. concentration.	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Griess assay was performed according to the literature procedure.135 In this assay, 2 mM 
solution of the test compound in DMSO was mixed thoroughly with a freshly prepared solution 
of L-cysteine and incubated at 37 °C for 1 h and 16 h under anaerobic conditions. Organic 
nitrates require specific thiols such as L-cysteine as co-activators for the release of NO. Thiols 
form S-nitroso adducts which consequently release NO. The non-enzymatic reaction of              
L-cysteine in vitro is thought to mimic the enzymatic-metabolism of nitrate esters in vivo.136       
In vivo, thiols play a regulatory role in targeting NO to the RBCs. It may also be useful in 
facilitating NO transportation, prolonging its half-life and alleviate its cytotoxic effects.137-139 
Griess reagent was added to each test compound, followed by absorbance measurement at 540 
nm. Presence of NO!! results in the formation of a pink color, the intensity of which is directly 
proportional to the amount of NO!! present in the mixture. Table 4 represents NO!! release for 
compounds TD-1, TD-7-1, TD-8 and TD-9.    
Table 4. Absorbance and NO!! release values for TD-1, TD-7-1, TD-8-1 an TD-9-1 
 
Incubation Time 
(Hours) 
𝐍𝐎𝟐!  releasea (μM) 
after 1 hour 
𝐍𝐎𝟐! releasea (μM) 
after 16 hours 
TD-1 4.02 11.93 
TD-7-1 7.61 59.25 
TD-8-1 21.94 102.54 
TD-9-1 20.45 78.66 
aThe 𝑁𝑂!! release (μM) was calculated from the standard NaNO2 curve by extrapolating the 
absorbance (nm) of the test compounds against the concentration (μM) of NaNO2. 
 
All four compounds (TD-1, TD-7-1, TD-8-1 and TD-9-1) exhibited nitric oxide release 
(4.0 – 21.9 μM range at 1 h and 59 – 102.5 μM range at 16 h) upon incubation in the presence of 
L-cysteine. The NO release after 16 h incubation was found to be 3-10 fold higher than 1 h 
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incubation. From Table 4, it can be interpreted that for all the compounds, the NO release in the 
form of NO!! is found to increase with time, with TD-1 showing the least release, while TD-8-1 
showed the most release.  
 
iii. In vitro RBC morphological (anti-sickling) studies with compounds 5HMF, TD-1, TD-7 
and TD-7-1 
Our collaborators, Drs. Toshio Asakura and Osheiza Abdulmalik, from the Children’s 
Hospital of Philadelphia (CHOP), conducted the in vitro RBC morphological (anti-sickling) 
analysis. The anti-sickling effects of 5HMF, TD-7, TD-1, and TD-7-1 were studied by 
incubating suspensions of SS cells in the absence or presence of three different concentrations of 
the effectors in the presence of air for 1 h at 37 °C followed by incubation under 4% O2 at 37°C 
for 5 h. Table 5 represents the concentrations of the effectors along with the % inhibition of 
sickling cells. 
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Table 5. Effects of various concentrations of compounds on inhibition of SS cell sickling.  
Compound Concentration 
(mM) 
Sickled cells (%) Inhibition of 
sickled cells (%) 
5HMF 
1.0 83 17 
2.0 65 35 
5.0 25 75 
INN-312 
0.5 85 15 
1.0 66 44 
2.0 5 95 
TD-7 
0.5 5 95 
1.0 5   95 
2.0 0 100 
TD-8 
0.5 78 14 
1.0 72 20 
2.0 56 38 
TD-9 
0.5 67 26 
1.0 59 35 
2.0 38 57 
TD-7-1 
0.5 25, most round cells 72 
1.0 All spherocytes, more hemolysis - 
2.0 Hemolysis, no sickled cells 100 
All samples were pre-incubated for 1 h with various compounds and then incubated under 4% 
O2 for 5 h. Hb had a hematocrit of 30%. 
 
Figure 14 represents a graph of sickling inhibition (%) vs. drug concentration (mM). 
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Figure 14. Inhibition of sickling of SS cells by test compounds under 4% O2 at 37 °C for 5 h. 
In the absence of test compounds, more that 90% of the Hb underwent sickling in 5 h. In 
the presence of the positive control, 5HMF, the percentage of the sickled cells decreased in a 
dose-dependent manner with ~35% inhibition at 2 mM concentration. INN-312, the second-
generation positive control, also decreased the percent of sickled cells in a dose-dependent 
manner and inhibited sickling by ~ 95% at 2 mM concentration. Comparing the % inhibition of 
5HMF and INN-312 at 2 mM concentration, it can be seen that INN-312 is almost 3-fold more 
effective in its anti-sickling properties. Remarkably TD-7 showed a very potent anti-sickling 
effect, as much as 95% inhibition at 0.5 mM concentration. A plateau effect was observed as the 
concentration of TD-7 was increased. Although, TD-8 and TD-9 showed sickling inhibition in a 
dose dependent manner, they did not show as much sickling inhibition as TD-7. TD-8 and TD-9 
showed % inhibition of ~ 40% and ~ 60% at 2 mM concentrations. TD-7-1, the nitrate ester 
analog of TD-7, showed anti-sickling effect but with significant hemolysis with increased 
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concentration from 0.5 mM to 2 mM. The RBCs were observed to swell due to possible 
intracellular uptake of water.    
 
C. Structural studies 
i. Structural studies of deoxy-Hb in complex with TD-7: 
The X-ray structure of the most potent left-shifter, TD-7 in complex with Hb was studied 
to elucidate the structural basis of its allosteric and anti-sickling activities. To obtain the co-
crystals between Hb and TD-7, Hb was deoxygenated under vacuum, followed by incubation of 
the drug, and then crystallized using either low-salt condition (0.2 M sodium acetate trihydrate, 
0.1 M sodium cacodylate trihydrate pH 6.5 and 30% w/v PEG 8000) or high-salt condition (3.2-
3.6 M sulfate/phosphate precipitant, pH 6.5), all under anaerobic conditions. For the high-salt 
crystallization experiment, we observed two crystal forms; the first crystal which was bigger, and 
rectangular in shape and purple in color formed in 3-5 days; the second crystal which appeared in 
about 2 months later was much smaller, trigonal bipyrimidal in shape and reddish in color.  
Similar observations have been reported with left-shifting compounds when co-crystallized with 
deoxy-Hb.106,118 It has been suggested that in a complex mixture of deoxy-Hb and a left-shifting 
agent, binding of the AEH to the deoxy-Hb slowly shifts the allosteric equilibrium to the R-state, 
increasing the concentration of the R-state Hb, which eventually crystallizes out after deoxy-Hb 
crystals have been formed earlier.103 Diffraction dataset are yet to be collected for either crystal 
forms since the R crystals are too small for diffraction. 
We also co-crystallized deoxy-Hb with TD-7 using low-salt condition. Only one crystal 
form (deoxy-Hb) was observed which was dark purple and rectangular in shape and grew to a 
size of about 0.2 x 0.3 x 0.4 mm in 3-5 days. Diffraction data was collected, and the crystal 
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belonged to P21212 space group. The structure of the deoxy-Hb T-state crystal was determined 
by a molecular replacement method with the program Phenix140 using the native human deoxy-
Hb structure (2HHB)26 and the structure refined with the program CNS.141 Detailed 
crystallographic data is summarized in Table 6.  
The electron density map of complex between deoxy-Hb and TD-7 showed sparse and 
broken difference electron density at the α-cleft in a symmetry-related fashion, suggesting very 
weak compound binding in two positions (Figure 15). Similar observations have been reported 
with other left-shifters bound to T-state structures, which has been suggested to be due to a very 
large binding pocket in deoxy-Hb precluding tighter binding, as well as inability of these 
compounds to make any inter-subunit interactions with the deoxy-Hb.118 As a result of weak 
binding to deoxy-Hb, it is suggested that these molecules, instead of stabilizing the T-state, 
rather, destabilize it, shifting the allosteric equilibrium to the R-state. In contrast, left-shifters are 
known to bind strongly to the R-state Hb by forming several intersubunit interactions with both 
α-subunits, resulting in strong compound densities in this Hb state.118 Due to the weak density 
for TD-7, detailed and specific interactions between the molecule and the protein are not 
warranted.  Nonetheless, from the weak electron density, we could ascertain that the compound 
forms a Schiff base interaction with the α1Val1 N, directing the hydroxymethyl-pyridine-
methoxy substituent upwards and towards the mouth of the α-cleft (Figures 16 and 17) as 
previously observed for INN-312.106 The hydroxymethyl-pyridine-methoxy substituent of TD-7 
is directed upwards even further as compared to the pyridine-methoxy substituent of INN-312, 
which was consistent with our prediction.106 The bound compound is close and/or appears to 
make hydrophobic and/or direct or water-mediated hydrogen-bond interactions with α1Pro77, 
α1Asp74, α1Asp75, α1Ser131, α2Thr134, and α2Thr137. Some of these interactions have been 
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observed in the INN-312 structure.106 The apparent hydrophobic contact with α1Pro77 and 
water-mediated interaction with α1Asp75 or α1Asp74 (residues that are on the surface of the 
protein) is most interesting as the adjacent residue α1Asn78 has been implicated in Hb S polymer 
contact (Figure 18).58 Thus contact between TD-7 and these residues could lead to destabilization 
of the Hb S polymer as previously suggested.103  
Although, we are yet to collect diffraction data for the R-state crystal, it is anticipated that 
like INN-312,106 TD-7 would also bind to the α-cleft of the oxygenated Hb very strongly to tie 
the two α-subunits of the liganded Hb together that would stabilize and shift the allosteric 
equilibrium to the R-state. Also, the binding would direct the hydroxymethyl-pyridine-methoxy 
substituent toward the surface of the protein as observed in the above deoxy-Hb structure, as well 
as in the previously published R-state structure in complex with INN-312.106 
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Table 6. Crystallographic data and refinement statistics for compound TD-7: Hb complex  
Parameters TD-7 
Data-collection Statistics: 
Space group P21212 
Unit-cell parameters (Å) 63.2 82.8 110.9 90.0 90.0 90.0 
Molecules in asymmetric unit 1 
Resolution (Å) 29.78 – 2.00 (2.07 – 2.00) 
No. of measurements 148961 
Unique reflections (I/σ(I)) 33027 
Avg redundancy 4.51 (4.46) 
Completeness (%) 82.4 (89.9) 
Rmerge (%) 0.096 (0.355) 
Structure Refinement: 
Resolution limits (Å) 30.00 – 2.00 
No. of reflections 32997 (82.4%) 
R factor (%) 24.02 
Rfree (%) 29.59 
R.m.s.d from standard geometry: 
Bond lengths (Å) 0.009 
Bond angles (°) 1.46 
Dihedral angles: 
Most favored (%) 540 (95.74) 
Allowed regions (%) 21 (3.72) 
Average B factors (Å) 
All atoms 30.8 
Protein 30.7 
Heme 29.4 
Water 37.2 
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Figure 15. Binding of a pair TD-7 molecules (green sticks) at the α-cleft of Hb with the α (α1- 
blue; α2- grey) and β (β1- magenta; β2- yellow) chains. 
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Figure 16. A pair of TD-7 molecules (green stick) bound at the α-cleft of T-state Hb making 
Schiff base interactions with αVal1 N (blue and grey sticks), as well as showing disposition of 
the hydroxymethyl moiety towards the surface of the molecule to make contact with the surface 
F helix residues.  For brevity, not all residues making contact with the molecule are shown. 
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Figure 17. Binding of a pair TD-7 molecules (green sticks) to the F-helix of Hb with α (α1- blue; 
α2- grey) chains. 
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Figure 18. Two-dimensional schematic of contacts between TD-7 and the surrounding Hb 
residues.  
 
 
 
 
 
 
 
α2Thr134 
α2Thr137 
α2Ser138 
α1Ser131 α1Val1 
α1Pro77 
α1Met76 α1Asp75 
α1Asp74 
α1Val73 
	  
	  
64	  
	  
ii. Structural studies of deoxy-Hb in complex with TD-1 
We have also determined the crystal structure of TD-1 (nitrate ester derivative of 5HMF) 
to explain its allosteric activity. To obtain co-crystals, Hb was deoxygenated under vacuum, 
followed by incubation of the drug, and then crystallized using high-salt condition (3.2-3.6 M 
sulfate/ phosphate, pH 6.5) under anaerobic conditions.  Only T-state crystals were obtained 
belonging to P21 space group, and isomorphous to known native T-state crystal (2HHB).26 The 
crystals were dark purple and rectangular in shape and grew to about 0.2 x 0.3 x 0.4 mm in         
3-5 days. Detailed crystallographic data is summarized in Table 7. The isomorphous native 
deoxy-Hb structure (2HHB) was used for structure refinement.26 The initial electron density map 
showed two molecules of TD-1 forming Schiff base interactions with αVal1 N of both α-
subunits at the α-cleft in a symmetry-related fashion (Figures 19 and 20). Unlike TD-7, the 
ligand density of TD-1 was very strong and well defined, allowing unambiguous fitting of the 
ligand into the density for subsequent refinement. This is in contrast with 5HMF (the parent 
compound), which like all left-shifters binds weakly to T-state Hb.118 Obviously, the apparent 
strong binding of TD-1 to the T-state Hb is consistent with its significantly less left-shifting 
effect as binding to the T-state leads to apparent stabilization of this allosteric form.  
In addition to the Schiff base interaction with the α1-subunit, the TD-1 furan oxygen 
forms inter-subunit water-mediated hydrogen bonds with the symmetry-related α2-subunit with 
the amide oxygen of α2Ser138 and the carboxyl atom of α2Arg141 (Figure 21). The ester 
oxygen makes hydrogen-bond interaction with the amine of α2Arg141, while the two free nitro 
oxygens make either interaction with a water molecule or with the amide oxygen of α2Thr137. 
These interactions serve to tie the α1 and α2 subunits together and stabilize the T-state Hb. The 
second TD-1 molecule binds in a symmetry-related fashion to the first TD-1 molecule. Although, 
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refinement of the structure suggested the bound compound to be mostly the non-hydrolyzed 
nitrate ester analog, there is some presence of the hydrolyzed 5HMF. The fact that most of the 
bound compound is the nitrate ester analog which apparently is stabilizing the T-state structure, 
is consistent with the functional/biological studies that show limited left-shifting and/or anti-
sickling effect of this compound. Thus, for this compound to be effective as an anti-sickling 
agent, it must release the NO prior to binding to Hb and not bind as the nitrate ester. 
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Table 7. Crystallographic data and refinement statistics for compound TD-1: Hb complex 
Parameters TD-1 
Data-collection Statistics: 
Space group P21 
Unit-cell parameters (Å) 62.3 82.0 53.5 90.0 99.5 90.0 
Molecules in asymmetric unit 1 
Resolution (Å) 29.92 – 1.80 (1.86 – 1.80) 
No. of measurements 187917 
Unique reflections (I/σ(I)) 46300 
Avg redundancy 4.06 (3.81) 
Completeness (%) 94.1 (89.4) 
Rmerge (%) 0.039 (0.082) 
Structure Refinement: 
Resolution limits (Å) 30.0 – 1.8 
No. of reflections 46300 (94.1%) 
R factor (%) 16.71 
Rfree (%) 19.22 
R.m.s.d from standard geometry: 
Bond lengths (Å) 0.010 
Bond angles (°) 1.566 
Dihedral angles: 
Most favored (%) 548 (96.82%) 
Allowed regions (%) 17 (3.72%) 
Average B factors (Å) 
All atoms 15.1 
Protein 12.8 
Heme 10.6 
Water 27.8 
TD-1 30.9 
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Figure 19. Binding of a pair TD-1 molecules (green sticks) at the α-cleft of Hb with α (α1- blue; 
α2- grey) and β (β1- magenta; β2- yellow) chains. 
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Figure 20. Binding of a pair TD-1 molecules (green sticks) to the F-helix of Hb with α (α1- blue; 
α2- grey) chains. 
 
 
 
 
Figure 21. Two-dimensional schematic of contacts between TD-1 and the surrounding Hb 
residues. Narrow dashed lines indicate hydrogen bond and electrostatic interactions. 
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D. Stability studies of left-shifting nitrate ester compounds 
Nitrate esters are known to be unstable and easily prone to hydrolysis.144 The stability of the 
nitrate ester derivatives were checked by performing UPLC-MS on previously prepared stock 
solutions of the nitrate ester compounds (TD-1, TD-7-1, TD-8-1 and TD-9-1). 100 µM stock 
solutions were prepared in DMSO and stored for 3 months at −20°C during which time it was 
exposed to at least 6 freeze-thaw cycles. It was observed that the compounds were stable, 
suggesting no degradation. 
 
Objective 2: Allosteric effectors of Hb (AEH) that decrease the oxygen affinity of Hb (right-
shifting of the OEC) with the capability of releasing nitric oxide (NO) 
A. Synthesis of nitrate ester derivative of RSR-13 
RSR-13 is an allosteric effector of Hb that acts by decreasing Hb affinity for O2, and as a 
result allows release of more O2 to tissues.15 We decided to incorporate a nitrate ester moiety 
onto RSR-13. We propose that, in vivo, the NO will cleave off, resulting in the parent compound 
and free NO, the former acting as right-shifter while the latter is released into the vasculature.  
Compound DD-1 (44), a nitrate ester derivative of RSR-13, was synthesized as shown in Scheme 
X. 2-Bromoethanol (57) was nitrated using a nitrating mixture of 95% sulfuric acid and 75% 
nitric acid at 0 °C to yield 58 which was coupled with RSR-13 (30) under basic conditions to 
yield 44 in 83% yield. 
 
 
	  
	  
70	  
	  
SCHEME X: Synthesis of compound 44a 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  
aReagent: (a) H2SO4, HNO3, CH2Cl2, room temperature, 3 h; (b) RSR-13 (30), K2CO3, 
anhydrous DMF, room temperature, 24 h. 
 
B.  In-vitro functional studies 
i.  Oxygen equilibrium studies 
a. Time-dependent OEC studies with DD-1 and RSR-13 with whole blood: 
The effect of the nitrate ester derivative of RSR-13 (DD-1) was also studied using whole 
blood with RSR-13 as a positive control. The solution of DD-1 and RSR-13 was added to 2 mL 
of whole blood (Hemocrit of ~ 29%) to make a final drug concentration of 2 mM.                 
Time-dependent studies were carried out at various time points (ranging from 1 h to 12 h) at      
37 °C, equilibrated in a tonometer with oxygen tensions of 6%, 20% and 60% for 5-7 min each, 
and pO2 and sO2 values were measured thereafter.  
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Table 8. Effect of incubation time on Hb affinity for O2 with normal whole blood for right-
shifting compounds. 
Compound 
Incubation 
Time (Hours) 
P50 
(mmHg) 
Na 
ΔP50b 
(mmHg) 
Control 
1 32.5 2.6 - 
2 32.9 2.7 - 
4 33.6 2.6 - 
8 34.9 2.5 - 
12 37.0 2.5 - 
RSR-13 
1 47.8 1.8 15.3 
2 47.9 1.9 15.0 
4 49.7 1.8 16.1 
8 51.8 1.8 16.9 
12 52.6 1.9 15.6 
DD-1 
1 35.7 2.3 3.2 
2 39.2 2.1 6.3 
4 49.9 1.9 16.3 
8 60.3 1.7 25.4 
12 64.8 1.7 27.8 
All samples were pre-incubated with whole blood (Hct ~ 29%) with the specified compounds       
at 2 mM concentrations for the specified time. aHill coefficient; bΔP50 is (P50 (control)–P50 
(sample)) expressed in mmHg. The control experiment without test compound (P50 (control)) 
contains the same concentration of DMSO used to solubilize the test solution (P50 (sample)).  
 
The results showed a gradual increase in the P50 values with time, with a maximum P50 
after 12 h incubation. Initially, P50 value of DD-1 was lower than that of the parent compound 
but as the incubation time crossed 4 h, the P50 value of DD-1 was seen to increase over the parent 
compound.  Based on these results, it can be construed that the nitrate ester analog, DD-1, has a 
better O2 releasing capacity as compared to RSR-13 after 4 h of incubation. 
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Figure 22. Time dependent studies of DD-1 and RSR-13 showing changes in P50 with incubation 
time. 
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ii. Nitric oxide release study for DD-1  
 
Griess assay was used to measure the NO releasing ability of DD-1 following the 
literature procedure (also used for the left-shifting compounds).133 NO!! release from the 
compound was calculated by extrapolating the absorbance of the test compound against the 
concentration of NaNO2 in the standard NaNO2 curve (Figure 13). Table 9 represents NO!! 
release for compound DD-1. 
Table 9. Absorbance and NO!! release values for Compound DD-1. 
 
Incubation Time 
(Hours) 
𝐍𝐎𝟐! release (μM) after 1 
hour 
𝐍𝐎𝟐! release (μM) after 16 
hours 
DD-1 9.61 5.35 
aThe 𝑁𝑂!! release (μM) was calculated from the standard NaNO2 curve by extrapolating the 
absorbance (nm) of the test compounds against the concentration (μM) of NaNO2. 
 
Unlike the nitrate esters of the left-shifting agents, the NO!! release from DD-1 after 1 h 
incubation was found to be much higher than that after 16 h incubation. DD-1 released NO!! but 
significantly less than the left-shifting compounds shown above in Table 4. This suggests that the 
potent OEC effect is most likely due to the binding of the non-hydrolyzed DD-1 to deoxy-Hb. 
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C. Structural studies 
i. Crystallographic results of DD-1: 
 The crystal structure of DD-1 was determined in complex with deoxy-Hb, to elucidate 
the structural basis of its allosteric activity. To obtain co-crystals, Hb was deoxygenated under 
vacuum, followed by incubation of the drug, and then crystallized using low-salt condition      
(0.2 M sodium acetate trihydrate, 0.1 M sodium cacodylate trihydrate pH 6.5 and 30% w/v PEG 
8000) under anaerobic conditions. The crystals were dark purple, rectangular in shape and 
formed quickly growing to a size of about 0.2 x 0.3 x 0.4 mm in 3-5 days. The crystal has space 
group P21212. Detailed crystallographic data is summarized in Table 10. The structure was 
determined by molecular replacement method with the program Phenix,140 using the deoxy-Hb 
structure in complex with RSR-13 (PDB ID: 1G9V)28 as the search model.  The structure was 
refined with the program CNS.141  
The electron density map showed two well defined DD-1 bound in a symmetry-related 
manner at the middle of the central water cavity (Figures 23 and 24); similar to what was 
previously observed for RSR-13.28 Interestingly, the structure showed a mixture of the nitrate 
ester analog (DD-1) and the hydrolyzed analog (RSR-13) and were refined together. In addition 
to the bound DD-1, we also observed a 2,3-DPG molecule, bound at the β-cleft (Figure 24). 
Apparently, 2,3-DPG was present in the Hb that was used for the crystallization experiment. 
Sephadex G25 and extensive dialysis were used to purify the Hb which did not lead to complete 
removal of 2,3-DPG, suggesting that a more extensive purification process is required to 
completely exclude out the 2,3-DPG. Interestingly, even though the same Hb was used to co-
crystallize with the left-shifting agent, TD-7, we did not observe any significant bound 2,3-DPG 
at the β-cleft. This could be explained by the fact that binding of the potent right-shifter, DD-1, 
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increased the T-state character of the deoxy-Hb which led to stronger affinity for 2,3-DPG. On 
the other hand, the binding of the potent left-shifter TD-7 seemed to decrease the T-state 
character of deoxy-Hb which reduced 2,3-DPG binding. 
 Each DD-1 molecule forms interactions with 3 subunits, 2 α-subunits and 1 β-subunit in a 
symmetry-related fashion (Figure 25). Relatively weak electron density was observed for the 
nitrooxyethylene moiety of the compound, suggesting the bound compound to be a mixture of 
hydrolyzed RSR-13 and non-hydrolyzed DD-1. The nitrate group is involved in direct hydrogen-
bond interaction with the hydroxyl of α1Thr134, water-mediated hydrogen bond interactions 
with amide nitrogen of α1Val1 and hydroxyl of α1Ser131 as shown in Figure 26. The oxygen 
adjacent to the carbonyl group forms water-mediated hydrogen bond interaction with the amide 
nitrogen of α1Thr134, as well as inter-subunit water-mediated hydrogen bond interaction with 
the amine of α2Arg141, the latter observed in RSR-13 binding.28 Also, similar to RSR-13 
binding,28 the isopropyl group and phenyl group makes several intra- and inter-subunit 
hydrophobic interactions with β1Tyr35, β1Trp37, α2Thr137, α2Tyr140 and α2Pro95, while the 
carbonyl oxygen makes direct hydrogen bond interactions with the amine of α1Lys99. The 
amide nitrogen is also involved in several water-mediated interactions with α1His122, 
α1Asp126, while the dimethylbenzene ring makes hydrophobic interactions with α1Phe36, 
α1Val96, α1His103 and α1Leu100. As previously noted,28 these interactions serve to tie three of 
the subunits together stabilizing the deoxy-Hb to shift the allosteric equilibrium to the T-state 
and decreasing the O2 affinity of Hb. It is interesting to note that irrespective of whether the 
compound is the hydrolyzed RSR-13 or the non-hydrolyzed DD-1, it binds the T-state Hb in 
similar fashion.28 
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Table 10. Crystallographic data and refinement statistics for compound DD-1: deoxy-Hb 
complex 
 
Parameters DD-1 
Data-collection Statistics: 
Space group P21212 
Unit-cell parameters (Å) 95.9 98.4 65.4 90.0 90.0 90.0 
Molecules in asymmetric unit 1 
Resolution (Å) 29.54 – 1.85 (1.92 – 1.85) 
No. of measurements 291228 
Unique reflections (I/σ(I)) 52662 
Avg redundancy 5.53 (4.00) 
Completeness (%) 98.2 (94.3) 
Rmerge (%) 0.084 (0.313) 
Structure Refinement: 
Resolution limits (Å) 30 – 1.85 
No. of reflections 52628 (98.2%) 
R factor (%) 22.38 
Rfree (%) 26.38 
R.m.s.d from standard geometry: 
Bond lengths (Å) 0.12 
Bond angles (°) 1.67 
Dihedral angles: 
Most favored (%) 539 (95.97) 
Allowed regions (%) 25 (4.43) 
Average B factors (Å) 
All atoms 24.1 
Protein 22.1 
Heme 20.5 
Water 35.4 
DD-1 48.7 
2,3- DPG 43.7 
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Figure 23. Binding of a pair DD-1 molecules (green sticks) to three subunits of deoxy-Hb with α 
(α1- blue; α2- grey) and β (β1- magenta; β2- yellow) chains. 
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Figure 24. Binding of a pair of DD-1 molecules (green sticks) to 2α (blue and grey ribbons) and 
1β subunit (magenta ribbon) at the middle of the central water cavity, and binding of 2,3-DPG 
molecules in two alternate conformations (dark green sticks) to the β-cleft (magenta and yellow 
ribbons). 
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Figure 25.	  	  Contacts between DD-1 molecules (green sticks) and the protein (α chains- blue and 
grey lines, β chains- magenta and yellow lines).  
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DD-1: 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	    
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   
 
 
 
Figure 26. Two-dimensional schematic of contacts between DD-1 and surrounding Hb residues. 
Narrow dashed lines indicate hydrogen bond and electrostatic interactions; broad dashed lines 
hydrophobic contacts. 
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D. Stability studies of DD-1 
Nitrate esters are known to be unstable and easily prone to hydrolysis.144 The stability of nitrate 
ester was checked by performing UPLC-MS on previously prepared stock solution of DD-1. 100 
µM stock solution was prepared in DMSO and stored for 3 months at −20°C during which time it 
was exposed to at least 6 freeze-thaw cycles. It was observed that DD-1 was stable, suggesting 
no degradation. 
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DISCUSSION 
 
 
 
1. Allosteric effectors of Hb that increase the oxygen affinity of Hb (left-shifting of the 
OEC) with or without the capability of releasing NO  
Sickle cell disease is a hemoglobinopathy which is caused by an abnormal defect in the 
β-globin chain of Hb.20 Since hydroxyurea is the only clinically useful drug approved for the 
treatment of SCD,59,60,118 there is a need for novel anti-sickling left-shifting agents which would 
be beneficial in treating SCD. Hb S in sickle cells has low O2 affinity with a P50 value of           
32 ± 2 mmHg as compared to 26 ± 2 mmHg for normal RBCs.106 This leads to premature release 
of O2 prior to reaching tissues and organs, depriving them of O2, resulting in hypoxia. In 
addition, increased de-oxygenation of Hb S leads to polymerization and sickling of RBC, 
eventually resulting in hemolysis. Therefore, one of the potential treatment options for SCD 
would be to design compounds that could increase the O2 affinity of Hb S to prevent the 
premature release of O2 as well as decrease the concentration of deoxy-Hb S.  
This has encouraged the study of several aromatic aldehydes that are known to increase 
the O2 affinity of Hb, by forming Schiff base adducts between the aldehyde moiety and the 
amino group of N-terminal Val1 at the α-cleft of both deoxy-Hb and oxy-Hb.103,107,118 This 
interaction leads to destabilization of the deoxy-Hb and/or stabilization of the oxy-Hb, shifting 
the allosteric equilibrium to the high O2 affinity R-state Hb. The compound-modified Hb S acts 
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similarly as normal Hb, preventing premature release of oxygen, and releasing just enough O2 in 
the capillaries but not extensively to reach the critical deoxy-Hb concentration to polymerize.39 
Two such studied compounds include 5HMF and vanillin. 5HMF, is currently being studied 
clinically for the treatment of SCD,18 while vanillin has previously been studied for its anti-
sickling activity, both in vitro and in vivo, as well as clinically.103 INN compounds, belonging to 
the series of pyridyl derivatives of vanillin or substituted benzaldehydes (INN-270, INN-296, 
INN-298, and INN-312), were synthesized by our group to improve on the pharmacologic 
properties of vanillin.103 Some of these compounds exhibited more than 70-fold anti-sickling 
activity as compared to  vanillin, and 2.5-fold more than 5HMF.103,119 More interestingly, some 
of the INN compounds (those with the pyridine-methoxy substituent ortho to the aldehyde 
moiety), e.g., INN-312 exhibit dual anti-sickling activity by increasing Hb affinity for O2, as well 
as destabilizing Hb S polymer contact as a result of the displacement of the pyridine-methoxy 
moiety towards the surface of the protein.106 Even those compounds with the pyridine-methoxy 
substituent (meta to the aldehyde moiety, e.g., INN-298) directed down the central water cavity, 
also showed significant anti-sickling activity as a result of several additional interactions 
between the pyridine-methoxy substituent and protein.106 
  Based on the positive outcome of the modification of vanillin to obtain the INN 
compounds, our group decided to further improve on the allosteric, anti-sickling and 
pharmacokinetic properties of these compounds, as well as combine their anti-sickling activities 
with NO releasing capability.  First, analogs of the previously studied INN compounds103 were 
synthesized by replacing the ether linkage between the pyridine and benzaldehyde rings to an 
ester linkage to yield TD-2 and amide linkage to yield TD-3. The synthesis was carried out as per 
Scheme I and II.  The final step in the synthesis of compound 50 (Scheme II) involved reduction 
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of the nitro group to the corresponding amine. Various reaction conditions were carried out such 
as Fe/HCl, Fe/AcOH, Fe/HCl with NH4Cl and hydrogenation with Pd/C, all of which resulted in 
poor yields, which could be attributed to the formation of inter- and/or intra-molecular Schiff 
base formation between the aldehyde and the amino group. The reaction conditions of Fe/HCl 
gave the best yield (17%) amongst the rest, and hence was the method used for the synthesis of 
compound 50. The syntheses of TD-2 and TD-3 were carried out by simple base catalyzed 
reactions in the presence of pyridine to give the desired products in fairly good yields. Second, 
hydroxymethyl group was incorporated onto the pyridine ring which would either extend the 
hydroxymethyl-pyridine-methoxy substituent further down the central water cavity to increase its 
binding affinity (for compounds that have the substituent meta to the aldehyde) or extend the 
hydroxymethyl-pyridine-methoxy substituent to the surface of the protein (for compounds that 
have the substituent ortho to the aldehyde) and thus increase its direct polymer destabilization 
property. Accordingly, the INN analogs including TD-7, TD-9 and TD-8 with hydroxymethyl 
substituents on the pyridine rings were synthesized as shown in schemes III – V.  The syntheses 
of TD-7, TD-9 and TD-8 were carried out by straight forward base catalyzed reactions in the 
presence of K2CO3 to give the desired products in fairly good yields.  
A major pathophysiology of SCD is the vascular NO deficiency which is caused due to 
NO scavenging by free hemolyzed Hb. To prevent vaso-constriction and inflammation 
characterized by this deficiency, exogenous NO, either in the form of gas inhalation or via 
organic compound has been studied for making NO bioavailable to SCD patients.44,108 
The hydroxymethyl substituents on the compounds 5HMF, TD-7, TD-8 and TD-9 were 
esterified with NO releasing moiety. It was proposed that these nitrate esters would hydrolyze in 
vivo to release NO and make available to the vasculature, while the parent aromatic aldehydes 
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would bind to Hb and display their anti-sickling activities. The syntheses were carried out as per 
schemes VI - IX resulting in the compounds TD-1, TD-7-1, TD-9-1 and TD-8-1. 5HMF was 
converted directly to its nitrate ester analog (TD-1, Scheme VI) using LiNO3 and TFAA. Similar 
reaction condition was tried for the synthesis of TD-7-1, however the reaction was unsuccessful. 
Hence, a two-step approach was undertaken which involved conversion of the hydroxymethyl 
group to its corresponding bromomethyl, followed by reaction with AgNO3 to yield TD-7 
(Scheme VII). Similarly, TD-9 (Scheme VIII) and TD-8 (Scheme IX) were synthesized. 
Following the synthesis, the compounds were tested for their effect on Hb affinity for 
oxygen, their ability to release NO, their effect on RBC sickling and finally X-ray structure 
determination to gain insight into their allosteric properties.  
 
A. Modification of the ether bridge of pyridyl derivatives of benzaldehydes with an ester 
or amide resulted in compounds that decrease Hb oxygen affinity 
The compounds with an ester or amide bridge were hypothesized to bind to Hb and shift 
the O2 equilibrium to the R-state. Unexpectedly, TD-2 did not significantly affect Hb allosteric 
property, while TD-3 significantly right-shifted the OEC to decrease Hb affinity for O2 (Table 1). 
This suggests that these compounds, especially TD-3 may not be suitable for the treatment of 
SCD as they could potentially promote polymerization by increasing the concentration of the less 
soluble deoxy-Hb S molecules. Structural studies on atomic level are yet to be performed to 
understand the reason why these molecules acted opposite to what was expected. The inactivity 
of TD-2 could be probably attributed to aldehyde dehydrogenase (ALDH) metabolism or 
metabolism by esterases inside the RBCs that cleave or metabolize the ester linkage and 
inactivate it. It is possible the amide analog (TD-3) binds strongly to deoxy-Hb and stabilize the 
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T-state Hb, leading to a shift in the allosteric equilibrium to the low O2 affinity Hb. It has been 
noted that, aromatic aldehydes with carboxylate groups on the aromatic ring decrease Hb affinity 
for O2 by binding strongly to deoxy-Hb and stabilize the T-state.142 Replacement of the 
carboxylate with a methoxy group, such as in vanillin disrupts these intersubunit interactions in 
the T-state, resulting in weak binding to the T-state structure but stronger binding to the R-state 
structure, leading to left-shift of the OEC.118  
Although the OEC results for these compounds are unexpected, because of the significant 
right-shifting ability of TD-3, it could be potentially useful for the treatment of ischemic-related 
diseases. Remarkably, it is as potent as RSR-13, which has been studied for several ischemic-
related diseases.14,143 
 
B.  Substitution of hydroxymethyl group on the pyridine ring of pyridyl derivatives of 
benzaldehydes resulted in compounds that increase Hb oxygen affinity 
As noted above, some INN compounds, such as INN-312 are known to bind to the α-cleft 
of Hb and extend its pyridine-methoxy moiety (ortho to the aldehyde) toward the surface of the 
protein.103 This leads to destabilization of polymer contacts in deoxy-Hb. Such molecules exhibit 
dual anti-sickling activity; increasing Hb S O2 affinity, as well as preventing direct Hb S polymer 
contact. Even though other INN compounds, such as INN-298, have the pyridine-methoxy 
moiety (meta to the aldehyde) extended further down to the central water cavity,103 the added 
hydrophobic/hydrogen-bond contacts with the protein due to the pyridine-methoxy moiety leads 
to significant left-shifting potency. Based on this consideration, analogs of three INN compounds 
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were prepared by adding hydroxymethyl moiety on the pyridine rings to obtain TD-7, TD-8 and 
TD-9.  
Expectedly, all three compounds resulted in left-shifting of the OEC in whole blood 
(increase in Hb affinity for O2) amongst which TD-7 was found to be the most potent (-17.0 
mmHg) at 2 mM, followed by TD-9 (-10.2 mmHg) and lastly TD-8 which showed a significantly 
low left-shifting effect of -5.5 mmHg (Table 1). TD-7 was found to be more potent than the 
positive control, 5HMF. The results also compare with the previously studied INN-312, INN-298 
and INN-296 with ΔP50 of ~ -17, -14 and -16 mmHg, respectively at 2 mM drug concentration.119 
It is obvious, however, that these three compounds may be equipotent (as observed) using cell-
free Hb for the OEC study (Table 2). These results suggest that the presence of plasma proteins, 
serum enzymes and RBC cell membrane do play an interfering role on the activity of the 
compounds in whole blood. In the absence of these interfering components of the whole blood 
(as in the case of cell-free Hb), the compounds directly act on the Hb molecule and cause an 
effect, which can be seen by comparing the results of whole blood and cell-free Hb. Therefore, 
the low biological activity of TD-8 and TD-9 could be attributed to plasma protein binding 
and/or RBC membrane permeability. It has been previously studied that plasma or RBC 
membrane does not interfere significantly with 5HMF, INN-312, INN-298 and INN-296 binding 
to Hb.18,106  
TD-7 also exhibits time-dependent allosteric profile in whole blood (Table 3, Figure 12). 
From the previous concentration-dependent studies (Table 1), it was seen that 0.5 mM was the 
lowest concentration at which TD-7 showed left-shifting activity. Thus, 0.5 mM concentration 
was chosen for time-dependent studies. We observed extended left-shifting activity for TD-7 
with no recovery even at 12 h. In contrast, 5HMF activity peaked between 2-6 h and began to 
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recover to the baseline after 6 h. This suggests that it’s the sustained effect of TD-7 may provide 
an advantage in chronic use in the prophylaxis of SCD crises. Our previous study with INN-298 
and INN-312 also resulted in similar long duration effect.119  
Compounds that increase the O2 affinity of Hb exhibit anti-sickling activity since the high-
O2-affinity Hb S does not polymerize.55-57 Therefore the effect of TD-7 on sickle RBC 
morphology was studied by our collaborators, Drs. Asakura and Abdulmalik (CHOP). As 
expected from its left-shifting ability, TD-7 also prevented sickling of RBC in a dose dependent 
manner (Table 5 and Figure 14). As shown in Table 5, the anti-sickling effect of this compound 
was found to be ~6-fold more effective than 5HMF and ~2-fold more effective than INN-312 at 
1 mM concentration.103 It was observed that as the concentration of TD-7 was increased from    
0.5 mM to 1 mM, a plateau effect was observed with 95% inhibition of sickling at both the 
concentrations. On further concentration increase, complete inhibition (100% inhibition) was 
observed. This remarkable increase in the anti-sickling activity is not explainable by the left-
shifting ability alone, and it suggests an additional mode of anti-sickling effect, which possibly 
could be due to Hb S polymer destabilization, as hypothesized. As compared to TD-7, the 
positional isomers, TD-8 and TD-9, were seen to be ~5-fold and ~3-fold less effective anti-
sickling agents respectively. 
We co-crystallized TD-7 with deoxy-Hb to understand its mechanism of action. Our 
study with TD-7 using high-salt condition resulted in both T-state and R-state crystals, however, 
while the former crystals were big enough to diffract, the latter were too small for diffraction. 
We are yet to collect data for any of these crystals. However, we determined the structure of the 
T-state Hb in complex with TD-7 with crystals obtained with low-salt crystallization conditions. 
We anticipate this structure to be similar to the structure from the high-salt crystal.  
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The structure shows two molecules of TD-7 bound in a symmetry-related fashion at the 
α-cleft of deoxy-Hb. Similar to other anti-sickling aromatic aldehydes, TD-7 is also weakly 
bound.118 Nevertheless, the weak and broken density allows us to model the approximate 
position of the bound compound, which shows the aldehyde making a Schiff base interaction 
with the N-terminal amine of α1Val1. The hydroxymethyl-pyridine-methoxy substituent was 
also seen to point upwards, towards the mouth of the central water cavity, as previously observed 
with INN-312 where the pyridine-methoxy of INN-312 was observed to make close hydrophobic 
contact with αPro77.106 αPro77, as well as the residues αVal73, Asp74, αAsp75, αMet76, 
αPro77 and Asn78 are part of a helix (F-helix) located at the surface of the protein. The αF-helix 
residue, Asn78 has been implicated in stabilizing the Hb S fiber, and the Hb variant, Stanleyville 
(αAsn78 ↔ αLys78) is known to inhibit gelation.58 It was suggested that the contact between 
INN-312 and the αF-helix led to destabilization of polymer contact between the Hb S molecules, 
contributing to the significant anti-sickling activity of this compound, which was consistent with 
solubility studies.106 The fact that the pyridyl moiety of TD-7 also points toward this helix 
apparently making stronger hydrophobic interaction with Pro77 (Figure 16-18) could explain its 
significant anti-sickling activity. More significantly, we also observe what appear to be water-
mediated interactions between the hydroxyl of TD-7 and several of the helix residues which 
could even result in more polymer destabilization effect. Thus, the hydroxymethyl substituent we 
propose is playing a critical role in the anti-sickling property of some of the effectors, especially 
those that bind and extend outward toward the surface of the protein. 
In conclusion, we have been able to design and synthesize several left-shifting agents, with at 
least one of them exhibiting remarkable anti-sickling activity. Further studies, including 
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solubility study, in vivo studies with sickle mice are ongoing by our collaborators at CHOP.    
TD-8 and TD-9 are also currently being tested for their anti-sickling activities. 
 
C.  Nitrate esterification of anti-sickling aromatic aldehydes lead to compounds that 
increase Hb oxygen affinity, as well as make NO bioavailable 
Another reason for the synthesis of the hydroxymethyl analogs of INN compounds was to 
afford us compounds to attach a nitrate ester moiety to the hydroxymethyl substituent. 5HMF 
already had a hydroxymethyl moiety which was taken advantage for attaching a nitrate ester 
moiety. Nitrate esters are easily prone to hydrolysis,144 therefore experiments were performed to 
check the stability of the nitrate ester compounds. UPLC-MS was done on previously prepared 
stock solutions of the nitrate ester compounds (TD-1, TD-7-1, TD-8-1 and TD-9-1). 100 µM 
stock solutions were prepared in DMSO and stored for 3 months at −20°C during which time it 
was exposed to at least 6 freeze-thaw cycles. It was observed that the compounds were stable, 
suggesting no degradation, which provided evidence that the nitrate esters were intact and did 
not hydrolyze to NO and the parent compound prior to OEC studies and Griess assay studies.  
We hypothesize that in vivo the nitrate ester will be hydrolyzed to release NO to the 
vasculature, while the parent aromatic aldehyde will bind to Hb, shift the OEC to the left to 
increase the more soluble high-O2-affinity Hb fraction and thus prevent Hb S polymerization. 
The ester nitrate analogs of 5HMF, TD-7, TD-8 and TD-9 were synthesized to give TD-1,       
TD-7-1, TD-8-1 and TD-9-1 respectively.  
The effects of the compounds on Hb affinity for oxygen using whole blood were also 
studied (Tables 1 and Figure 11). Although the nitrate ester derivatives show left-shifting 
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abilities, their potencies were less than the parent compounds, which could partly be due to 
incomplete/slow nitrate ester hydrolysis and/or plasma protein binding and/or difficulties 
associated with RBC membrane permeability. Studies were conducted using cell-free Hb as 
shown in Table 2. It was seen that all the tested compounds, including the nitrate esters TD-7-1 
and TD-1, showed weaker left-shifting potency as compared to their parent compounds TD-7 
and 5HMF. This observation supports our hypothesis of incomplete/slow nitrate ester hydrolysis 
and/or the interference of plasma proteins and RBC cell membrane with the biological activity of 
the nitrate ester compounds. Studies on cell-free Hb with TD-8-1 and TD-9-1 are yet to be 
performed to test if these compounds behave in a similar manner. Most likely the nitrate ester 
derivatives did not completely hydrolyze to free the parent anti-sickling compound. Thus the 
non-hydrolyzed compound binds and stabilizes the T-state as observed in the crystallographic 
study for TD-1 (see below) to cancel out any anti-sickling effect of the free parent aromatic 
aldehyde. This could pose a major problem for SCD treatment, unless in vivo, significant 
hydrolysis could take place to free the parent compound.  
Nonetheless, we note that the compounds are capable of hydrolyzing to release NO. Due 
to the high reactivity of NO, extremely low concentrations (pM to nM range) are required for 
biological activity such as anti-inflammatory, vasodilatory activity and prevention of platelet 
aggregation.126 Nitric oxide release studies were performed on the nitrate ester derivatives; TD-1, 
TD-7-1, TD-8-1 and TD-9-1 as shown in Table 4.  It was observed that all the compounds 
released the NO!! in a time-dependent manner with TD-1 showing the least NO!! release while 
TD-8-1 showing maximum NO!! release as compared to the other nitrate ester compounds. These 
results suggest that the nitrate ester compounds have a potential of hydrolyzing and releasing NO 
to the vasculature, although the extent of the release is not clear without doing in vivo animal 
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studies. Such studies are planned in the future. Nevertheless, it is obvious that whether NO is 
released or the nitrate ester is intact, the compounds are able to maintain their left-shifting      
anti-sickling activities. 
Another significant observation is that the nitrate ester derivative of TD-7 (TD-7-1) 
resulted in significant hemolysis of the RBC, which could pose toxicity problem. The reason 
behind this behavior is unclear, but further studies are ongoing to determine the cause, as we do 
not see the same effect with TD-1.  
We also determined the crystal structure of TD-1 (nitrate ester derivative of 5HMF) in 
complex with deoxy-Hb to explain its weak allosteric and anti-sickling activity. The initial 
electron density map showed two molecules of TD-1 forming Schiff base interaction with αVal1 
amino group of both α-subunits at the α-cleft in a symmetry-related fashion (Figures 19 and 20). 
Unlike TD-7, the ligand density of TD-1 was very strong and well defined, allowing 
unambiguous fitting of the ligand into the density for subsequent refinement. This is in contrast 
with 5HMF, which like all left-shifters binds weakly to T-state Hb.118 The increased number of 
interactions (Figure 21) including inter-subunit water-mediated hydrogen bonds with α2Ser138 
and α2Arg141 and interactions with water molecules, serve to tie the α1 and α2 subunits together 
and stabilize the T-state Hb on TD-1 binding. The fact that most of the bound compound is the 
nitrate ester analog which apparently is stabilizing the T-state structure is consistent with the 
functional/biological studies that show weak left-shifting and/or anti-sickling effect of this 
compound. Thus, for this compound to be an effective anti-sickling agent, it must release the NO 
prior to binding to Hb and not bind as the nitrate ester. It is anticipated that this would occur in 
vivo, and plans are underway to test this compound in mice.  
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2. Allosteric effectors of Hb that decrease the oxygen affinity of Hb with the capability of 
releasing NO 
The discovery that 2,3-DPG decreases the O2 affinity of Hb to allow efficient release of 
O2 to tissues prompted the search for synthetic Hb effectors that act similarly to 2,3-DPG but are 
more potent and orally bioavailable for therapeutic purposes. Even as much as a 2 mmHg shift 
(in P50) in the OEC may represent a beneficial response that increases O2 delivery.14 This has 
culminated in the discovery of several aromatic propionates, including RSR-13 and several of it 
analogs.112 
RSR-13 is a potent Hb effector, which increases the O2 releasing capacity by decreasing 
Hb affinity for O2. It thus shifts the OEC curve to the right and stabilizes the T-state Hb. RSR-13 
was being studied in the phase III clinical trials as a radio-sensitizing agent,145 due to its property 
of releasing O2 to tumorous tissues. A potential problem with the use of right-shifting agent is 
excessive tissue oxygenation that induces vasoconstriction.131 Therefore; a right-shifting agent 
with the ability to release NO could potentially mitigate the problem of vasoconstriction by its 
vasodilatory property. The nitrate ester analog of RSR-13 was synthesized so as to perform as a 
dual acting agent, which delivers O2 to the tissues as well as releases NO to the vasculature. 
UPLC-MS analysis showed the nitrate ester to be stable in solution. 
The study with RSR-13 and DD-1 showed both compounds to shift the OEC to the right 
as previously observed for RSR-13.112 Time-dependent studies performed on DD-1 and RSR-13 
(Table 8) suggested that the P50 values of both compounds, increased consistently with time 
(Figure 22). Initially, P50 value of DD-1 was lower than that of the parent compound but as the 
incubation time crossed 4 h, the P50 value of DD-1 was seen to increase over the parent 
compound.  Based on these results, it can be interpreted that the nitrate ester analog, DD-1, has a 
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better O2 releasing capacity as compared to RSR-13 after 4 h, and possibly it is a slow binder 
compared to RSR-13.  
During the NO release studies performed with DD-1 (Table 9), it was observed that, 
unexpectedly, the NO!! release for 1 h was around 2-fold greater than the release after 16 h. 
Although it did show some NO!!  release, it was not as much as that seen for the left-shifting 
nitrate ester compounds. This suggests that the compound has a potential of releasing NO to the 
vasculature, although the extent of the release is not clear, without doing in vivo studies. Such 
studies are planned in the future. Nevertheless, it is obvious that whether that NO is released or 
the nitrate ester is intact, the compound is able to significantly decrease Hb affinity for oxygen. 
To understand the mechanism of action of DD-1, we co-crystallized deoxy-Hb with    
DD-1. The electron density map showed a mixture of two well defined densities of bound       
DD-1/RSR-13 molecules in a symmetry-related manner at the middle of the central water cavity 
(Figures 23 and 24); similar to what was previously observed for RSR-13,28 except for additional 
interactions by the nitrate ester moiety. Relatively, weak electron density was observed for the 
nitrooxyethylene moiety of the DD-1. The direct contacts as well as water-mediated interactions 
formed by each DD-1/RSR-13 molecule with 3 subunits, 2 α-subunits and 1 β-subunit, stabilize 
the T-state as noted in the result section. Additional interactions between the nitrooxyethylene 
moiety and the T-state Hb residues, lead to further stabilization of the T-state, which may explain 
the significant potency of DD-1 over RSR-13. This observation could help in explaining the 
OEC results, suggesting that hydrolyzed RSR-13 binds first to the Hb while binding of the nitrate 
ester derivative occurs later. Similar interactions are observed for DD-1 as previously observed 
for RSR-13.28 Interactions between αLys99 and carbonyl oxygen, and 3,5-dimethyl benzene 
interaction with the amide group of βAsn108, are essential for activity since these interactions 
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stabilize T-state Hb.28 Similar to RSR-13 binding, the methyl propionic acid moiety participates 
in water-mediated interactions with the side chain guanidinium of αArg141, which also 
constrains the T-state.28 The oxygen adjacent to the carbonyl group is also shown to form water-
mediated hydrogen bond interaction with the hydroxyl of α1Thr134. There are several water-
mediated interactions between the amide nitrogen of DD-1/RSR-13 and surrounding protein 
residues that contribute in stabilizing the T-state.  
The nitrate group is involved in direct hydrogen bond and water-mediated interactions 
with α1Thr134, α1Ser131, and α1Val1 as shown in Figures 25 and 26. These interactions add 
additional constraint to and stabilize the T-state Hb. Irrespective of whether the compound is the 
hydrolyzed RSR-13 or the non-hydrolyzed DD-1, it binds to the T-state Hb in a similar fashion 
so as to stabilize the T-state, which can be correlated with the OEC studies suggesting a similar 
right-shift (O2 releasing property) for both RSR-13 and DD-1 molecules.  
In addition to the DD-1/RSR-13 binding, we also observed a bound 2,3-DPG molecule at 
the β-cleft of Hb (Figure 24), which most likely leads to further stabilization of the T-state Hb. 
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CONCLUSIONS 
 
 
 
This project was focused on two objectives which included the synthesis, testing and structural 
studies of (1) Allosteric effectors of Hb (AEH) that increase the O2 affinity of Hb (left-shifting of 
the OEC) with or without the capability of releasing NO and (2) AEHs that not only decrease the 
O2 affinity of Hb (right-shifting of the OEC) but are also capable of releasing NO. The former 
compounds are being developed for treating SCD, while the latter for ischemic-related diseases. 
Under hypoxic conditions, Hb S undergoes intracellular polymerization to form 
polymerized fibers, which increases rigidity and decreases flexibility of the RBCs.117 Sickled 
RBCs are fragile and are prone to rupture or lysis to release free plasma Hb, a potent NO 
scavenger.44 Developing means to modify Hb S from low O2 affinity Hb to high O2 affinity Hb 
would help in preventing polymerization of Hb S and be beneficial in treating the complications 
of SCD.103,107,118 Moreover, delivering NO exogenously for therapeutic purposes or to enhance 
its endogenous production, would be highly effective in targeting the ramifications of NO 
deficiency.121 Therefore, development of AEHs which would increase the Hb O2 affinity and/or 
release NO was one of the objectives of this project.  
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Towards this objective, we synthesized 9 compounds, all analogs of the previously 
studied anti-sickling 5HMF and INN compounds that we proposed would bind to R-state Hb and 
increase its O2 affinity. Some of the compounds, especially those with the hydroxymethyl 
substituent on the pyridine ring showed left-shifting properties as predicted, with one of the 
compounds, TD-7, showing a remarkable anti-sickling effect, ~6-fold and ~2-fold more effective 
than 5HMF and INN-312 respectively, at the same concentration of 1 mM. Although more 
studies need to be performed to completely unravel TD-7’s anti-sickling mechanism, it is likely 
that in addition to it’s ability to increase the oxygen-affinity of Hb due to stabilization of the      
R-state Hb, it may also destabilize polymer contacts due to the extended hydroxymethyl-
pyridine-methoxy group directed towards the surface of the protein. Therefore TD-7 provides a 
new structural scaffold for further drug development for SCD. 
Two of the synthesized compounds, TD-2 and TD-3, were proposed to left-shift the OEC 
and increase the O2 affinity of Hb by making hydrogen bonding interactions with the R-state Hb. 
However, TD-3 instead of increasing Hb affinity for oxygen, unexpectedly resulted in the 
opposite effect.  It is possible the amide analog (TD-3) binds strongly to deoxy-Hb and stabilize 
the T-state Hb, leading to a shift in the allosteric equilibrium to the low O2 affinity Hb. 
Nevertheless, TD-3 could potentially be developed for the treatment of ischemic-related 
diseases. The ester analog, TD-2, was found to be inactive and did not affect the oxygen affinity 
of Hb. The inactivity of TD-2 could be probably attributed to aldehyde dehydrogenase (ALDH) 
metabolism or metabolism by esterases inside the RBCs that cleave or metabolize the ester 
linkage and inactivate it.  
Based on the fact that SCD is characterized by NO deficiency; as a result of scavenging 
by free Hb,44 we decided to derivatize some of the above compounds with nitrate esters, to 
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produce TD-1, TD-7-1, TD-8-1 and TD-9-1. These compounds are proposed to hydrolyze in vivo 
to make NO bioavailable to the vasculature, consistent with our in vitro study135 that show the 
release of NO in the presence of L-cysteine. It is also anticipated that the released aromatic 
aldehyde would bind to Hb S and left shift the OEC to increase the O2 affinity and hence the 
solubility of Hb S to prevent sickling.  
Several AEHs, such as RSR-13 that bind to Hb and decrease its oxygen affinity have 
been studied for use in ischemic-related diseases15,113 and as a radio-sensitizing agent.145 A 
potential problem in the use of these AEHs is the excessive tissue oxygenation which could 
induce vasoconstriction.130 A right-shifting agent with the ability to release NO could potentially 
mitigate this problem by its property of vasodilation. Therefore we synthesized the nitrate ester 
analog of RSR-13 (DD-1) to study both its right-shifting property as well as its potential to 
deliver NO to the vasculature. Not only did the compound show significant right-shifting 
activity, it also showed the release of NO, although not quite significantly, thus providing a 
potential dual-acting agent, which could be beneficial in the treatment of ischemia. However, it 
is also anticipated that more NO will be released in vivo.   
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EXPERIMENTAL 
 
 
 
1. Chemistry: 
General Information: Melting points were determined on a Fisher-Scientific melting point 
apparatus and were uncorrected. 1H-NMR and 13C-NMR spectras were obtained on a Brucker 
400 MHz spectrometer and tetramethylsilane (TMS) was used as an internal standard. Peak 
positions are given in parts per million (δ). Column chromatography was performed on silica gel 
(grade 60 mesh; Bodman Industries, Aston, PA). Routine thin-layer chromatography (TLC) was 
performed on silica gel GHIF plates (250 µm, 2.5 x 10 cm; Analtech Inc., Newark, DE). 
UHPLC-MS was recorded on a Perkin Elmer Flexar UHLPC with AxION 2 Time of Flight 
(TOF) Mass Spectrometer and the molecular weight of the compounds was within 0.05% of 
calculated values. Elemental analysis was performed by Atlantic Microlab Inc. (Norcross, GA) 
for the elements indicated and the results are within 0.4% of calculated values. Infrared spectra 
were obtained on a Thermo Nicolet iS10 FT-IR. Purity of the compounds was determined by 
HPLC using a Varian Microsorb 100-5 C18 column (250 x 4.6 mm), using Prostar 325 UV-Vis 
(254 nm) as the detector. 
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2-Formyl-4-methoxyphenyl isonicotinate (TD-2 or 35): 
 
Compound TD-2 (35) was prepared according to literature procedure for a similar compound.146 
Isonicotinylchloride hydrochloride (47) (0.35 g, 2.0 mmol) was added to a solution of 2-
hydroxy-5-methoxybenzaldehyde (46) (0.2 g, 1.3 mmol) in pyridine (10 mL) at 0 °C (ice-bath). 
The reaction mixture was allowed to stir at 50 °C for 2 h, diluted with CH2Cl2 (15 mL) and the 
solvent was evaporated under reduced pressure to yield a crude residue which was dissolved in 
CH2Cl2 (20 mL), washed with brine (2 x 10 mL), dried over Na2SO4 and evaporated to dryness 
under reduced pressure to yield a crude product, which was further purified by column 
chromatography (petroleum ether/EtOAc; 3:1), to yield 0.04g (12%) of 35 as a white-colored 
solid: mp 127-128 °C; IR (KBr, cm-1): 1733 (C=O); 1H-NMR (CDCl3): δ 3.89 (s, 3H, OCH3), 
7.22-7.23 (m, 2H, ArH), 7.41-7.42 (m, 1H, ArH), 8.01-8.03 (dd, J = 4.4, 1.6 Hz, 2H, ArH),     
8.88-8.89 (dd, J = 4.6, 1.4 Hz, 2H, ArH), 10.10 (s, 1H, CHO); 13C-NMR (CDCl3): δ 187.9, 
164.0, 158.0, 150.94, 144.9, 136.17, 128.45, 124.3, 123.24, 121.9, 114.0, 55.92. MS (ESI) m/z 
found 258.08 (M + H)+. The purity of the compound was checked by HPLC and was found to be 
97.8% pure. 
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N-(2-Formyl-4-methoxyphenyl) isonicotinamide (TD-3 or 36): 
 
Compound TD-3 (36) was prepared according to literature procedure of a similar compound.146 
Pyridine (0.12 mL, 1.45 mmol) was added to a solution of 2-amino-5-methoxybenzaldehyde (50) 
(0.15 g, 0.50 mmol) in anhydrous CH2Cl2 (20 mL). Isonicotinylchloride HCl (47) (0.26 g, 1.45 
mmol) was added and the reaction mixture was allowed to stir overnight at room temperature. 
The reaction mixture was diluted with CH2Cl2 (15 mL) and the solvent was evaporated under 
reduced pressure to yield a crude residue which was dissolved in CH2Cl2 (20 mL), washed with 
brine (2 x 10 mL), dried over Na2SO4 and evaporated to dryness under reduced pressure to yield 
a crude residue. The residue was purified by column chromatography (petroleum ether/EtOAc; 
3:1) to yield 0.04g (31%) of 36 as a yellow-colored solid: mp 165-166 °C; IR (KBr, cm-1): 3014 
(aromatic CH), 1686 (C=O), 1661 (NH-C=O); 1H-NMR (CDCl3): δ 3.90 (s, 3H, OCH3), 7.87 – 
7.89 (dd, J = 4.5, 1.6 Hz, 2H, ArH), 8.84 - 8.87 (m, 3H, ArH), 9.98 (s, 1H, NH), 11.95 (s, 1H, 
CHO); 13C-NMR (CDCl3): δ 195.71, 163.7, 155.79, 150.94, 150,94, 141.54, 134.14, 123.06, 
122.26, 121.89, 120.10, 117.2, 55.83. MS (ESI) m/z found 257.10 (M + H)+. The purity of the 
compound was checked by HPLC and was found to be 99.5% pure. 
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2-((6-(Hydroxymethyl)pyridin-2-yl)methoxy)-5-methoxybenzaldehyde (TD-7 or 37):   
 
Compound TD-7 (37) was prepared according to literature procedure for a similar compound.103 
A mixture of 2-hydroxy-5-methoxybenzaldehyde (46) (0.20 mL, 1.5 mmol), 6-(bromomethyl)-2-
pyridinemethanol (51) (0.30 g, 1.5 mmol), and K2CO3 (0.25 g, 1.8 mmol) in anhydrous DMF (20 
mL) was allowed to stir at room temperature for 12 h. The reaction mixture was diluted with 
EtOAc (20 mL), washed with H2O (2 x 20 mL), brine (2 x 10mL), dried over Na2SO4 and 
evaporated under reduced pressure to yield a crude product. The residue was purified by column 
chromatography (petroleum ether/EtOAc; 1:1) to yield 0.32g (78%) of 37 as a yellow-colored 
solid: mp 84-85 °C; IR (KBr, cm-1): 3396 (O-H), 1678 (C=O); 1H-NMR (CDCl3): δ 3.51 (s, 1H, 
OH), 3.81 (s, 3H, OCH3), 4.79 (s, 2H, CH2), 5.29 (s, 2H, CH2), 6.99 (d, J = 9.0 Hz, 1H, ArH), 
7.09-7.13 (dd, J = 9.0, 3.2 Hz, 1H, ArH), 7.21 (d, J = 7.7 Hz, 1H, ArH), 7.37 (d, J = 3.2 Hz, 1H, 
ArH), 7.43 (d, J = 7.6 Hz, 1H, ArH), 7.74 (t, 1H, ArH), 10.58 (s, 1H, CHO); 13C-NMR (CDCl3): 
δ 189.24, 158.80, 155.61, 154.17, 154.17, 137.66, 125.56, 123.40, 119.84, 119.64, 114.92, 
110.917, 71.65, 64.02, 55.86. MS (ESI) m/z found 274.15 (M + H)+, 296.14 (M + Na)+. The 
purity of the compound was checked by HPLC and was found to be 97.8% pure. 
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2-((6-(Hydroxymethyl)pyridin-2-yl)methoxy)-4-methoxybenzaldehyde (TD-9 or 38):   
 
Compound TD-9 (38) was prepared according to literature procedure for a similar compound.103 
A mixture of 2-hydroxy-4-methoxybenzaldehyde (52) (113 mg, 0.74 mmol), 6-(bromomethyl)-2-
pyridinemethanol (51) (150 mg, 0.74 mmol), and K2CO3 (123 mg, 0.90 mmol) in anhydrous 
DMF (20 mL) was stirred at room temperature for 12 h. The reaction mixture was diluted with 
EtOAc (20 mL), washed with H2O (2 x 20 mL), brine (2 x 10mL), dried over Na2SO4 and 
evaporated under reduced pressure to yield a crude product. The crude was purified by column 
chromatography (petroleum ether/EtOAc; 1:1) to yield 190 mg (94%) of 38 as a yellow-colored 
solid: mp 104-105 °C; IR (KBr, cm-1): 3153 (O-H), 1599 (C=O); 1H-NMR (CDCl3): δ 3.58 (s, 
1H, OH), 3.85 (s, 3H, OCH3), 4.78 (d, 2H, CH2), 5.30 (s, 2H, CH2), 6.53 (d, J = 2.2 Hz, 1H, 
ArH), 6.60 (d, J = 2.16 Hz, 1H, ArH), 7.22 (d, J = 7.68 Hz, 2H, ArH), 7.47 (d, J = 7.76 Hz, 2H, 
ArH), 7.76 (t, 1H, ArH), 7.85 (d, J = 8.64 Hz, 1H, ArH), 10.43 (s, 1H, CHO); 13C-NMR 
(CDCl3): δ 166.16, 162.27, 158.67, 155.51, 137.74, 131.04, 119.85, 119.69, 118.1, 106.68, 
99.16, 70.85, 63.87, 55.66. MS (ESI) m/z found 274.11 (M + H)+, 296.09 (M + Na)+.  The purity 
of the compound was checked by HPLC and was found to be 96.9% pure. 
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3-((6-(Hydroxymethyl)pyridine-2-yl)methoxy)-4-methoxybenzaldehyde (TD-8 or 39):   
 
Compound TD-8 (39) was prepared according to literature procedure for a similar compound.103 
A mixture of 3-hydroxy-4-methoxybenzaldehyde (53) (200 mg, 1.0 mmol), 6-(bromomethyl)-2-
pyridinemethanol (51) (152 mg, 1.0 mmol), and potassium carbonate (165 mg, 1.2 mmol) in 
anhydrous DMF (20 mL) was stirred at room temperature for 12 h. The reaction mixture was 
diluted with EtOAc (20 mL), washed with H2O (2 x 20 mL), brine (2 x 10mL), dried over 
Na2SO4 and evaporated under reduced pressure to yield a crude product. The crude was purified 
by column chromatography (petroleum ether/EtOAc; 1:1) to yield 220 mg (80%) of 39 as a 
white-colored solid: mp 120-121 °C; IR (KBr, cm-1): 3176 (O-H), 1681 (C=O); 1H-NMR 
(CDCl3): δ 3.65 (s, 1H, OH), 4.00 (s, 3H, OCH3), 4.78 (d, 2H, CH2), 5.32 (d, 2H, CH2), 7.03 (d, 
J = 8.72 Hz, 1H, ArH), 7.17 (d, J = 7.68 Hz, 1H, ArH), 7.44-7.51 (m, 3H, ArH), 7.71 (t, 1H, 
ArH); 13C-NMR (CDCl3): δ 190.66, 155.53, 154.95, 137.54, 130.11, 126.88, 119.99, 119.60, 
111.92, 110.98, 158.79, 71.40, 63.90, 56.22. MS (ESI) m/z found 274.11 (M + H)+, 296.09 (M + 
Na)+. The purity of the compound was checked by HPLC and was found to be 99.5% pure. 
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5-Nitrooxymethyl furfural (TD-1 or 40): 
 
Compound TD-1 (40) was prepared according to literature procedure for a similar compound.147 
Trifluoroacetic anhydride (5.5 mL, 2 mmol) was added to a suspension of lithium nitrate (2.7 g, 
2 mmol) in anhydrous CH3CN (30 mL) at 20 °C. The reaction mixture was stirred until clear (30 
min) and cooled to 0 °C (ice-bath). Sodium carbonate (4.2 g, 2 mmol) and 5-hydroxymethyl-2-
furfural (27) (2.5 g, 1 mmol) were added together and the reaction mixture was allowed to stirred 
for 7 h at 0 °C (ice-bath). The reaction mixture was poured into an ice-cold solution of saturated 
NaHCO3 and extracted with EtOAc (2 x 10 mL). The combined organic portion was washed 
with brine (10 mL), dried over Na2SO4 and evaporated under reduced pressure to yield a crude 
product. The crude residue was purified by column chromatography (petroleum ether/EtOAc; 
2:1) to afford 2.9 g (85%) of 40 as a colorless viscous oil:  IR (KBr, cm-1): 1678 (C=O), 1631, 
1276 (NO2), 845 (ON); 1H-NMR (CDCl3): δ 5.48 (s, 2H, CH2), 6.73 (d, J = 3.5 Hz, 1H, ArH), 
7.25 (d, J = 3.6, 1H, ArH), 9.68 (s, 1H, CHO); 13C-NMR (CDCl3): δ 177.9, 153.4, 151.5, 120.9, 
114.5, 65.4. Anal. Calcd for (C6H5NO5) C, 42.12; H, 2.95; N, 8.19. Found: C, 42.02; H, 2.86; N, 
8.26. The purity of the compound was checked by HPLC and was found to be 98.8% pure. 
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(6-((2-Formyl-4-methoxyphenoxy)methyl)pyridin-2-yl)methyl nitrate (TD-7-1 or 41)  
 
Compound TD-7-1 (41) was prepared according to literature procedure for a similar 
compound.148 Silver nitrate (76 mg, 0.45 mmol) was added to a solution of 2-((6-
(bromomethyl)pyridin-2-yl)methoxy)-5-methoxybenzaldehyde (54) (100 mg, 0.3 mmol) in 
anhydrous CH3CN (5 mL). The reaction mixture was allowed to stir at 80 °C for 2 h. The 
reaction mixture was ﬁltered through celite and washed with CH2Cl2 (15 mL), and evaporated 
under reduced pressure to yield a crude product. The crude residue was puriﬁed by column 
chromatography (petroleum ether/EtOAc; 5:1) to yield 80 mg (83.78%) of 41 as a white-colored 
solid: mp 92-93 °C; IR (KBr, cm-1): 1664 (C=O), 1632 (NO2), 1274 (NO2), 872 (ON); 1H-NMR 
(CDCl3): δ 3.81 (s, 3H, OCH3), 5.28 (d, 2H, CH2), 5.56 (s, 2H, CH2), 6.98 (d, J = 9.08Hz, 1H, 
ArH), 7.10-7.13 (dd, J = 9.08, 3.28 Hz, 1H, ArH), 7.33-7.37  (dd, J = 8.4, 3.24 Hz, 2H, ArH), 
7.53 (d, J = 7.84 Hz, 1H, ArH), 7.80 (t, 1H, ArH), 10.57 (s, 1H, CHO); 13C-NMR (CDCl3): δ 
189.18, 157.08, 155.20, 154.20, 152.50, 138.05, 125.52, 123.38, 121.27, 121.19, 114.85, 111.00, 
74.15, 71.51, 55.85. MS (ESI) m/z found 319.09 (M + H)+, 341.07 (M + Na)+. The purity of the 
compound was checked by HPLC and was found to be 94.5% pure. 
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(6-((2-Formyl-5-methoxyphenoxy)methyl)pyridin-2-yl)methyl nitrate (TD-9-1 or 42)   
 
Compound TD-9-1 (42) was prepared according to literature procedure for a similar 
compound.148 Silver nitrate (76 mg, 0.5 mmol) was added to a solution of 2-((6-
(bromomethyl)pyridin-2-yl)methoxy)-4-methoxybenzaldehyde (55) (100 mg, 0.3 mmol) in 
anhydrous CH3CN (5 mL). The reaction mixture was allowed to stir at 80 °C for 2 h. The 
reaction mixture was ﬁltered through celite and washed with CH2Cl2 (15 mL) and evaporated 
under reduced pressure to yield a crude product. The crude product was puriﬁed by column 
chromatography (petroleum ether/EtOAc; 5:1) to yield 53 mg (56%) of 42 as a white – colored 
solid: mp 70-71 °C; IR (KBr, cm-1): 1677 (C=O), 1285 (NO2), 871 (ON); 1H-NMR (CDCl3-d1): δ 
3.85 (s, 3H, OCH3), 5.29 (s, 2H, CH2), 5.56 (s, 2H, CH2), 6.52 (d, J = 2.16 Hz, 1H, ArH), 6.58-
6.61 (m, 1H, ArH), 7.34 (d, J = 7.68 Hz, 1H, ArH), 7.58 (d, J = 7.88 Hz, 1H, ArH), 7.79-7.85 
(m, 2H, ArH), 10.42 (s, 1H, CHO); 13C-NMR (CDCl3): δ 166.19, 163.05, 158.71, 155.53, 
138.15, 131.18, 121.31, 121.28, 118.15, 106.95, 99.07, 74.14, 70.80, 55.68. MS (ESI) m/z found 
341.08 (M + Na)+. The purity of the compound was checked by HPLC and was found to be 
99.8% pure. 
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(6-((5-Formyl-2-methoxyphenoxy)methyl)pyridin-2-yl)methyl nitrate (TD-8-1 or 43)  
 
Compound TD-8-1 (43) was prepared according to literature procedure for a similar 
compound.148 Silver nitrate (76 mg, 0.45 mmol) was added to a solution of 3-((6-
(bromomethyl)pyridine-2-yl)methoxy)-4-methoxybenzaldehyde (56) (100 mg, 0.3 mmol) in 
anhydrous CH3CN (5 mL). The reaction mixture was allowed to stir at 80 °C for 2 h. The 
reaction mixture was ﬁltered through celite and washed with CH2Cl2 (15 mL) and evaporated 
under reduced pressure to yield a crude product. The crude was puriﬁed by column 
chromatography (petroleum ether/EtOAc; 5:1) to yield 94 mg (98%) of 43 as a yellow-colored 
solid: mp 43-44 °C; IR (KBr, cm-1): 1683 (C=O), 1632 (NO2), 850 (ON); 1H-NMR (CDCl3): δ 
3.99 (s, 3H, OCH3), 5.31 (s, 2H, CH2), 5.57 (s, 2H, CH2), 7.02 (d, J = 8.24 Hz, 1H, ArH), 7.31 
(d, J = 7.68 Hz, 1H, ArH), 7.46 (d, J = 2.16 Hz, 1H, ArH), 7.49-7.52 (dd, J = 8.2, 1.76 Hz, 1H, 
ArH), 7.55 (d, J = 7.76 Hz, 1H, ArH), 9.82 (s, 1H, CHO); 13C-NMR (CDCl3): δ 190.56, 157.157, 
155.01, 152.01, 152.47, 148.42, 137.91, 130.20, 126.78, 121.34, 121.00, 112.24, 111.08, 74.27, 
71.43, 56.24. MS (ESI) m/z found 341.08 (M + Na)+. The purity of the compound was checked 
by HPLC and was found to be 96.9% pure. 
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2-(Nitrooxy)ethyl 2-(4-(2-((3,5-dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2-
methylpropanoate (DD-1 or 44): 
 
Compound DD-1 (44) was prepared according to literature procedure for a similar compound.103 
RSR-13 (5.8 g, 17 mmol) (30) and K2CO3 (5.5 g, 40 mmol) were added to a solution of 2-
bromoethyl nitrate (58) in anhydrous DMF (40 mL). The reaction mixture was allowed to stir for 
24 h at room temperature, was diluted with EtOAc (150 mL), washed with H2O (3 x 40 mL), 
dried over MgSO4 and evaporated under reduced pressure to give a crude product. The crude 
residue was purified by column chromatography (petroleum ether/EtOAc; 2:1) to yield 7.12g 
(97.4%) of 44 as a white-colored solid: mp 74-75 °C; IR (KBr, cm-1): 1741 (C=O), 1379 (NO), 
1276 (NO2), 1143 (CO), 845 (ON); 1H-NMR (CDCl3): δ 1.63 (s, 6H, CH3), 2.26 (s, 6H, CH3), 
3.48 (d, J = 4.8 Hz, 2H, CH2), 3.64 (s, 2H, CH2), 4.09-4.15 (dd, J = 14.32, 7.16 Hz, 2H, CH2), 
5.29 (s, 1H, NH), 6.73 (s, 1H, ArH), 6.86 (d, J = 8.52 Hz, 2H, ArH), 7.04 (s, 2H, ArH), 7.19 (d, J 
= 8.52 Hz, 2H, ArH); 13C-NMR (CDCl3): δ 173.83, 169.04, 154.74, 138.64, 138.64, 137.48, 
130.39, 10.39, 128.40, 126.15, 119.69, 119.69, 117.54, 117.54, 30.03, 60.96, 4.09, 25.38, 25.38, 
21.26, 21.26. MS (ESI) m/z found 431.18 (M + H)+. The purity of the compound was checked by 
HPLC and was found to be 97.3% pure. 
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5-Methoxy-2-nitrobenzaldehyde (49): 
 
Compound 49 was prepared as described.149 Methyl iodide (0.41 mL, 6.5 mmol) was added in a 
drop wise manner to a suspension of 5-hydroxy-2-nitrobenzaldehyde (1.0 g, 6.0 mmol) (48) and 
K2CO3 (0.83 g, 6.0 mmol) in anhydrous DMF (20 mL) at 0 °C (ice-bath) and the reaction 
mixture was allowed to stir at room temperature for 12 h. The reaction mixture was filtered and 
the filtrate was diluted with CH2Cl2 (10 mL), evaporated under reduced pressure to yield a crude 
residue, dissolved in EtOAc (20 mL), washed with H2O (2 x 10 mL), brine (2 x 10 mL), dried 
over Na2SO4 and evaporated to dryness under reduced pressure to yield a crude residue which 
upon recrystallization using petroleum ether/EtOAc yielded 1.02g (94%) of 49 as an off-white 
colored solid: mp 80-81 °C (lit150 mp 81-82 °C); 1H-NMR (CDCl3): δ 3.96 (s, 3H, OCH3), 7.14-
7.17 (dd, J = 9.0, 2.8 Hz, 1H, ArH), 7.34 (d, J = 2.8 Hz, 1H, ArH), 8.17 (d, J = 9.0 Hz, 1H, 
ArH), 10.49 (s, 1H, CHO).  
 
2-Amino-5-methoxybenzaldehyde (50): 
 
Compound 50 was prepared as described.151 5-Methoxy-2-nitrobenzaldehyde (0.15 g, 0.8 mmol) 
(49), iron powder (0.46 mg, 8.3 mmol), and conc. HCl (2 drops), were added to EtOH/H2O (4:1, 
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5 mL) and the reaction mixture was allowed to stir at 95 °C for 2 h. The reaction mixture was 
filtered, diluted with water (10 mL) and extracted with EtOAc (3 x 10mL). The combined 
organic portion was washed with saturated NaHCO3 (2 x 10mL), H2O (2 x 10 mL), dried over 
Na2SO4 and evaporated under reduced pressure to yield a crude product. The crude was then 
purified by column chromatography (petroleum ether/EtOAc; 20:1) to yield 0.02 g (16.5%) of 50 
as a yellow oil: 1H-NMR (CDCl3): δ 3.79 (s, 3H, OCH3), 5.83 (s, 2H, NH2), 6.62 (d, J = 8.8 Hz, 
1H, ArH), 6.96 – 7.02 (m, 2H, ArH), 9.85 (s, 1H, CHO). The following compound was used for 
the synthesis of TD-3 (36). 
 
2-((6-(bromomethyl)pyridin-2-yl)methoxy)-5-methoxybenzaldehyde (54): 
 
Compound 54 was prepared according to literature procedure for a similar compound.148 
Triphenylphosphine (140 mg, 0.6 mmol) and tetrabromomethane (180 mg, 0.6 mmol) was added 
to a solution of 2-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-5-methoxybenzaldehyde (100 mg, 
0.4 mmol) (37) in anhydrous CH2Cl2 (6 mL). The reaction mixture was allowed to stir for 2 h at 
room temperature. The reaction mixture was neutralized with saturated NaHCO3 at 0 °C (ice-
bath) and extracted with EtOAc (10 mL). The organic portion was washed with brine (2 x 10 
mL), dried over Na2SO4 and evaporated under reduced pressure to yield a crude product. The 
crude was puriﬁed by column chromatography (petroleum ether/EtOAc; 5:1) to yield 100 mg 
(74.6%) of 54 as a yellow – colored solid: 1H-NMR (CDCl3): δ 3.81 (s, 3H, OCH3), 4.56 (s, 2H, 
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CH2), 5.28 (d, 2H, CH2), 6.98 (d, J = 9.08 Hz, 1H, ArH), 7.10 – 7.13 (dd, J = 9.08, 3.28 Hz, 1H, 
ArH), 7.33 – 7.37 (dd, J = 8.4, 3.24 Hz, 2H, ArH), 7.53 (d, J = 7.84 Hz, 1H, ArH), 7.80 (t, 1H, 
ArH), 10.58 (s, 1H, CHO). The following compound was used for the synthesis of TD-7-1 (41). 
 
2-((6-(bromomethyl)pyridin-2-yl)methoxy)-4-methoxybenzaldehyde (55): 
 
Compound 55 was prepared according to literature procedure for a similar procedure.148 
Triphenylphosphine (140 mg, 0.6 mmol) and tetrabromomethane (180 mg, 0.6 mmol) was added 
to a solution of 2-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-4-methoxybenzaldehyde (100 mg, 
0.4 mmol) (38) in anhydrous CH2Cl2 (6 mL). The mixture was allowed to stir for 2 h at room 
temperature. The reaction mixture was neutralized with saturated NaHCO3 at 0 °C (ice-bath) and 
extracted with EtOAc (10 mL). The organic portion was washed with brine (2 x 10 mL), dried 
over Na2SO4 and evaporated under reduced pressure to yield a crude product. The product was 
puriﬁed by column chromatography (petroleum ether/EtOAc; 5:1) to yield 100 mg (75%) of 55 
as a yellow-colored solid: 1H-NMR (CDCl3): δ 3.85 (s, 3H, OCH3), 4.56 (s, 2H, CH2), 5.30 (s, 
2H, CH2), 6.53 (d, J = 2.16 Hz, 1H, ArH), 6.57-6.59 (m, 1H, ArH), 7.40 (d, J = 7.72 Hz, 1H, 
ArH), 7.50 (d, J = 7.8 Hz, 1H, ArH), 7.76 (t, 1H, ArH), 7.84 (t, J = 8.68 Hz, 1H, ArH), 10.43 (s, 
1H, CHO). The following compound was used for the synthesis of TD-9-1 (42). 
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3-((6-(Bromomethyl)pyridine-2-yl)methoxy)-4-methoxybenzaldehyde (56): 
 
Compound 56 was prepared according to literature procedure for a similar compound.148 
Triphenylphosphine (140 mg, 0.6 mmol) and tetrabromomethane (180 mg, 0.6 mmol) was added 
to a solution of 3-((6-(hydroxymethyl)pyridine-2-yl)methoxy)-4-methoxybenzaldehyde (100 mg, 
0.4 mmol) (39) in anhydrous CH2Cl2 (6 mL). The mixture was allowed to stir for 2 h at room 
temperature. The reaction mixture was neutralized with saturated NaHCO3 at 0 °C (ice-bath) and 
extracted with EtOAc (10 mL). The organic portion was washed with brine (2 x 10 mL), dried 
over Na2SO4 and evaporated under reduced pressure to yield a crude product. The crude was 
puriﬁed by column chromatography (petroleum ether/EtOAc; 5:1) to yield 76 mg (56.5%) of 56 
as a yellow-colored solid: 1H-NMR (CDCl3-d1): δ 3.99 (s, 3H, OCH3), 4.56 (s, 2H, CH2), 5.31 (s, 
2H, CH2), 7.02 (d, J = 8.2 Hz, 1H, ArH), 7.38 (d, J = 7.8 Hz, 1H, ArH), 7.46 (d, J = 7.8 Hz, 1H, 
ArH), 7.49 (d, J = 1.84 Hz, 1H, ArH), 7.52 (d, J = 1.76 Hz, 1H, ArH), 7.72 (t, 1H, ArH), 9.82 (s, 
1H, CHO). The following compound was used for the synthesis of TD-8-1 (43). 
 
 
 
 
 
	  
	  
114	  
	  
2-Bromothyl nitrate (58): 
 
Compound 58 was prepared as described.152 Sulfuric acid (95%, 4.8 mL) was added in a drop 
wise manner to nitric acid (75%, 2.2 mL) at 0 °C (ice-bath). The mixture was allowed to stir for 
10 min and 2-bromoethanol (2.5 g, 20 mmol) (57) in CH2Cl2 (20 mL) was added in a drop wise 
manner and mixture was allowed to stir for 3 h at room temperature. The mixture was poured 
into H2O (100 mL), extracted with CH2Cl2 (3 x 50 mL), dried over MgSO4, and evaporated 
under reduced pressure to give crude 58. 1H-NMR (CDCl3): δ 3.55 (t, 2H, CH2), 4.75 (t, 2H, 
CH2). The crude was used immediately without purification for the synthesis of compound DD-1 
(44).  
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2. Blood collection and purification of hemoglobin  
Human blood samples for OEC studies were obtained from healthy volunteers at Virginia 
Commonwealth University. Hemoglobin for OEC and crystallographic studies was purified from 
RBCs left over from red cell exchange from the Medical College of Virginia Hospital. The use 
of the biological samples has been reviewed and approved by the IRB, in accordance of 
institutional regulations.  
Purification of Hb for OEC studies and crystallization was performed according to the 
literature procedure.153,154 Hemoglobin was prepared from centrifuging human blood at 2500 
rpms for 20 min at 4 °C. The supernatant solution, debris and plasma were discarded from the 
centrifuge bottles, leaving behind RBCs. The RBCs were washed thrice with an excess volume 
of 0.9% NaCl, and once with 1.0% NaCl, each time centrifuging and discarding the supernatant 
solution. The RBCs were pooled together into a chilled flask and hemolyzed to free Hb by 
adding 1-2 volume excess of 50 mM Tris buffer, pH 8.6 (containing EDTA). The mixture was 
allowed to stand in ice for 30 min with occasional stirring. The Hb solution was centrifuged at 
10,000 rpm for 2 h at 4 °C. The supernatant Hb solution was pooled into a chilled flask and NaCl        
(40-60 mg/mL Hb solution) was slowly added with stirring. Hemoglobin solution was 
centrifuged at 10,000 rpm for 2 h at 4 °C to remove any cell stroma remnants. The clear 
supernatant Hb solution was pooled into a chilled flask and the “syrupy” pellet was discarded. 
Hemoglobin solution was dialyzed against 50 mM Tris buffer, pH 8.6 (containing EDTA) at       
4 °C to remove NaCl and/or other low molecular weight impurities. Strips of standard cellulose 
dialysis tubing that had been washed 3-4 times and boiled for 10 min in deionized water were 
used for dialysis. The dialyzed Hb was further purified by ion-exchange chromatography using 
DEAE sephacel to exclude 2,3-DPG. The resin was equilibrated with 50 mM Tris buffer, pH 8.6, 
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and the Hb solution was run through the column with 50 mM Tris buffer, pH 8.6 (containing 
EDTA). The pooled fractions were concentrated with an Amicon stirred cell (Amicon, Model 
402), to a final HbA concentration of about 80-120 mg/mL. Concentrated HbA was stored at        
-80 °C. 
 
3.  Oxygen equilibrium curve studies 
Compounds that bind to Hb and increase its O2 affinity are potential anti-sickling agents, while 
those that decrease the protein affinity for O2 are potential agents to treat ischemic- and hypoxic-
related diseases. The OEC study was conducted therefore to determine whether these compounds 
have any effect on Hb affinity for O2 following reported procedure.103 Purified Hb or whole 
blood from normal subjects was used for this study. The OEC studies were conducted on whole 
blood samples with hematocrit values ranging from 29-36%, and cell-free purified Hb of           
10-12 g/dL in the absence or presence of effectors solubilized in DMSO at 2 mM or in some 
cases with varying compound concentration.  The blood samples were incubated in IL 237 
tonometer (Instrumentation Laboratories, Inc., Lexington, MA) for about 5-7 min at 37 ºC 
against gas mixture containing O2 concentrations of 0.804%, 2.935% and 5.528% or 0.804%, 
2.935% and 8.785% and allowed to equilibrate at O2 tensions of 6, 20, 40 mmHg or 6, 20, 60 
mmHg. After equilibration, the sample was removed via syringe and aspirated into a ABL 700 
series table top automated blood gas analyzer (Radiometer America, Inc., Westlake, OH) to 
determine total hemoglobin (tHb), hematocrit (Hct), pH, pCO2, partial pressure of oxygen (pO2), 
and the Hb oxygen saturation values (sO2). Similar procedure was followed for concentration 
and time dependent studies.  The measured values of pO2 and sO2 at each oxygen saturation level 
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were then subjected to a non-linear regression analysis using the program Scientist (Micromath, 
Salt Lake City, UT) with the following equation:  
sO!% = 100  × pO!!mmHgP!"! (mmHg)+   pO!!(mmHg) 
This equation was used to calculate P50 and Hill coefficient (N) values. Corresponding control 
experiments without the test compound (P50control) but containing DMSO were also performed.  
 
A. Oxygen equilibrium studies for left – shifting compounds 
For compounds proposed to shift the OEC to the left, blood samples with hematocrit 34-36%, 
were incubated against gas mixture containing O2 concentrations of 0.804%, 2.935% and 5.528% 
and allowed to equilibrate at O2 tensions of 6, 20, 40 mmHg and then used to obtain the partial 
pressure of oxygen (pO2), and the Hb O2 saturation values (sO2).  
 
B. Oxygen equilibrium studies for right – shifting compounds 
For compounds proposed to shift the OEC to the right, blood samples with hematocrit 29-32%, 
were incubated against gas mixture containing O2 concentrations of 0.804%, 2.935% and 8.785% 
and allowed to equilibrate at O2 tensions of 6, 20, 60 mmHg and then used to obtain the partial 
pressure of oxygen (pO2), and the Hb oxygen saturation values (sO2).  
  
4.  Griess assay (Nitric oxide detection assay) 
The key to the effectiveness of the proposed nitrate ester compounds is their ability to release 
NO and give back the parent compound to be able to interact with the vasculature and the Hb 
molecule, respectively, to exert their beneficial effects. This study was therefore conducted to 
determine the extent of NO release by these compounds following a literature procedure.134 
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Solution of the test compound (1 mL of a 2 mM solution in 0.1 M phosphate buffer (pH 7.4)) 
was mixed thoroughly with a freshly prepared solution of L-cysteine (1 mL of a 36 mM solution 
in 0.1 M phosphate buffer, pH 7.4), and incubated at 37 °C, for 1 and 16 h under anaerobic 
conditions. After exposure to air for 10 min at 25 °C, an aliquot of the Griess reagent (1 mL) 
[freshly prepared by mixing equal volumes of 1.0% sulfanilamide (prepared and stored in 
aqueous 5% phosphoric acid) and 0.1% N-naphthylethylenediamine dihydrochloride in water] 
was added to equal volume (1 mL) of each incubation solution after mixing. After 10 min, 
absorbance was measured at 540 nm using a Hewlett Packard (Agilent) 8453 UV-visible 
Spectroscopy. NaNO2 solutions of 1-100 µM concentrations were used to prepare a standard 
nitrite curve of absorbance (nm) versus concentration (µM). The NO released (quantitated as NO!! release in µM) was calculated from the standard nitrite curve by extrapolation of the 
absorbance.  
 
 
5.  X-ray crystallography 
A. Crystallization and structure determination: 
Crystallization experiments have been conducted with deoxy-Hb in complex with several 
compounds, including TD-1, TD-7 and DD-1, using reported literature procedures.118,154 The 
experiment involved 40-60 mg/mL of Hb and about 4-25 molar excess of the AEH. To obtain the 
deoxy-Hb crystals, Hb solution was evacuated for at least 1 h to make deoxy-Hb solution. For 
non-aldehyde compounds, a few pellets of sodium dithionite (a reducing agent) were added to 
facilitate the deoxygenation process. The compound solubilized in DMSO or water was then 
added to the Hb and incubated for 30 min to 1 h. For compounds that are aldehydes, sodium 
cyanoborohydride (NaCNBH4) in 4-25 molar excess of Hb was added to reduce the reversible 
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Schiff base adduct formed between the amino group of Hb and the aldehyde to the corresponding 
irreversible alkylamine covalent bond. Subsequent crystallization of the compound-deoxy-Hb 
complex solutions in 10 mL test tubes was undertaken using high-salt precipitant of 3.2-3.6 M 
sulfate/ phosphate precipitant pH 6.5 or low-salt precipitant of 0.2 M sodium acetate trihydrate, 
0.1 M sodium cacodylate trihydrate pH 6.5 and 30% w/v PEG 8000. Ferrous citrate (50 µL), 
generated in situ by the reaction of ferrous sulphate and sodium citrate in water, was added to 
each of the crystallization tubes, which functioned as antimicrobial. Water was added to any tube 
that showed precipitation. The tubes were purged with nitrogen, tightly stoppered and stored in 
glass jars. Crystals suitable for mounting grew in 3-5 days. The entire crystallization experiment 
was performed in a glovebox under nitrogen atmosphere as described to prevent oxygenation of 
the deoxy-Hb to oxy-Hb and met-Hb forms.154,155  
Crystals obtained from the deoxy-Hb in complex with TD-1, TD-7 or DD-1 were used for 
X-ray diffraction data collection at 100K with a R-axis IV++ image-plate detector using CuKα 
x-rays (λ = 1.54 Å) from Rigaku Micro-MaxTM -007 x-ray source equipped with varimax 
confocal optics (Rigaku, The Woodlands, TX) operating at 40 kv and 20 mA. Prior to use, the 
crystals were washed in a cryo-protectant solution containing mother liquor and glycerol and 
then flash frozen. The collected data sets were processed with MSC d*TREK software program 
and the CCP4 suite of programs.156  
The structures were determined by a molecular replacement method with the program 
Phenix140 and refined with the program CNS.141 Model building and corrections were carried out 
using graphics programs TOM157 and Coot.158 
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(i) Structure determination of deoxy-Hb in complex with TD-1  
Crystallization of the deoxy-Hb in complex with TD-1 was undertaken using the high-salt 
condition. Deoxy-Hb or T-state dark purple, rectangular crystals grew to a size of about 0.2 x 0.3 
x 0.4 mm in 3-5 days. The structure was solved by molecular replacement using the native 
human deoxy-Hb structure (PDB ID: 2HHB)26 as the search model, and refined to an 
Rfactor/Rfree of 16.71%/ 19.22%. 
 
(ii) Structure determination of deoxy-Hb in complex with TD-7  
Crystallization of deoxy-Hb in complex with TD-7 was undertaken using the low-salt condition. 
Deoxy-Hb or T-state dark purple, rectangular crystals grew to a size of about 0.2 x 0.3 x 0.4 mm 
in 3-5 days. After a month, a different crystal form, reddish in color and trigonal bipyrimidal 
began to form in the same crystallization tube as the T-state crystals. These crystals are R-state 
crystals, which did not grow to a suitable size even after 10 months.  The structure was solved by 
molecular replacement using the native human deoxy-Hb structure (PDB ID: 2HHB)26 as the 
search model, and refined to an Rfactor/Rfree of 24.02%/29.59%. 
 
(iii) Structure determination of deoxy-Hb in complex with DD-1  
Crystallization of deoxy-Hb in complex with DD-1 was undertaken using the low-salt condition. 
Deoxy-Hb or T-state dark purple, rectangular crystals grew to a size of about 0.2 x 0.3 x 0.4 mm 
in 3-5 days. The structure was solved by molecular replacement using the deoxy-Hb structure in 
complex with RSR-13 (PDB ID: 1G9V)28 as the search model, and refined to an Rfactor/Rfree of 
22.38%/26.38%. 
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